Modulators of methyl modifying enzymes, compositions and uses thereof

ABSTRACT

Agents having the structural Formula (II) for modulating histone methyl modifying enzymes, compositions and uses thereof for instance as anti-cancer agents are provided herein.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to International Application No.PCT/US2013/025639, filed Feb. 11, 2013. International Application No.PCT/US2013/025639 claims priority to U.S. Provisional Application Ser.Nos. 61/597,695, filed Feb. 10, 2012, and 61/667,821, filed Jul. 3,2012. The entire contents of the aforementioned applications areincorporated herein by reference.

BACKGROUND OF THE INVENTION

Eukaryotic chromatin is composed of macromolecular complexes callednucleosomes. A nucleosome has 147 base pairs of DNA wrapped around aprotein octamer having two subunits of each of histone protein H2A, H2B,H3, and H4. Histone proteins are subject to post-translationalmodifications which in turn affect chromatin structure and geneexpression. One type of post-translational modification found onhistones is methylation of lysine and arginine residues. Histonemethylation plays a critical role in the regulation of gene expressionin eukaryotes. Methylation affects chromatin structure and has beenlinked to both activation and repression of transcription (Zhang andReinberg, Genes Dev. 15:2343-2360, 2001). Enzymes that catalyzeattachment and removal of methyl groups from histones are implicated ingene silencing, embryonic development, cell proliferation, and otherprocesses.

SUMMARY OF THE INVENTION

The present disclosure encompasses the recognition that methyl modifyingenzymes are an attractive target for modulation, given their role in theregulation of diverse biological processes. It has now been found thatcompounds of this invention, and pharmaceutically acceptablecompositions thereof, are effective as agents that stimulate activity ofhistone methyl modifying enzymes, including histone methylases andhistone demethylases. Such compounds have the general formula II:

or a pharmaceutically acceptable salt thereof, wherein each variable isas defined herein.

Compounds of the present invention, and pharmaceutically acceptablecompositions thereof, are useful for treating a variety of diseases,disorders or conditions, associated with a methyl modifying enzyme. Suchdiseases, disorders, or conditions include those described herein.

Compounds provided by this invention are also useful for the study ofmethyl modifying enzymes in biological and pathological phenomena; thestudy of intracellular signal transduction pathways mediated by methylmodifying enzymes and the comparative evaluation of new methyl modifyingenzyme modulators.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1. Exemplary compounds of Formula II.

DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS 1. General Description ofCompounds of the Invention

In certain embodiments, the present invention provides a compound ofFormula II:

or a pharmaceutically acceptable salt thereof, wherein:

A is CH or N;

R^(1a) is selected from —C₁-C₂ alkyl and —O—(C₁-C₂ alkyl), whereinR^(1a) is optionally substituted with one or more fluoro;

R^(4a) is selected from —(C₁-C₄ alkylene)-O—(C₁-C₃ alkyl),1-substituted-pipieridin-4-yl, C₃-C₆ cycloalkyl optionally substitutedwith one or more fluoro, and tetrahydropyranyl; and

R¹³ is selected from hydrogen, halo, phenyl, pyridinyl, and —O—(C₁-C₄alkyl).

2. Compounds and Definitions

Definitions of specific functional groups and chemical terms aredescribed in more detail below. For purposes of this invention, thechemical elements are identified in accordance with the Periodic Tableof the Elements, CAS version, Handbook of Chemistry and Physics, 75^(th)Ed., inside cover, and specific functional groups are generally definedas described therein. Additionally, general principles of organicchemistry, as well as specific functional moieties and reactivity, aredescribed in Organic Chemistry, Thomas Sorrell, University ScienceBooks, Sausalito, 1999; Smith and March March's Advanced OrganicChemistry, 5^(th) Edition, John Wiley & Sons, Inc., New York, 2001;Larock, Comprehensive Organic Transformations, VCH Publishers, Inc., NewYork, 1989; Carruthers, Some Modern Methods of Organic Synthesis, 3^(rd)Edition, Cambridge University Press, Cambridge, 1987; the entirecontents of each of which are incorporated herein by reference.

Unless otherwise stated, structures depicted herein are also meant toinclude all isomeric (e.g., enantiomeric, diastereomeric, and geometric(or conformational)) forms of the structure; for example, the R and Sconfigurations for each asymmetric center, Z and E double bond isomers,and Z and E conformational isomers. Therefore, single stereochemicalisomers as well as enantiomeric, diastereomeric, and geometric (orconformational) mixtures of the present compounds are within the scopeof the invention. Unless otherwise stated, all tautomeric forms of thecompounds of the invention are within the scope of the invention.Additionally, unless otherwise stated, structures depicted herein arealso meant to include compounds that differ only in the presence of oneor more isotopically enriched atoms. For example, compounds having thepresent structures including the replacement of hydrogen by deuterium ortritium, or the replacement of a carbon by a ¹³C- or ¹⁴C-enriched carbonare within the scope of this invention. Such compounds are useful, forexample, as analytical tools, as probes in biological assays, or astherapeutic agents in accordance with the present invention.

Where a particular enantiomer is preferred, it may, in some embodimentsbe provided substantially free of the corresponding enantiomer, and mayalso be referred to as “optically enriched.” “Optically-enriched,” asused herein, means that the compound is made up of a significantlygreater proportion of one enantiomer. In certain embodiments thecompound is made up of at least about 90% by weight of a preferredenantiomer. In other embodiments the compound is made up of at leastabout 95%, 98%, or 99% by weight of a preferred enantiomer. Preferredenantiomers may be isolated from racemic mixtures by any method known tothose skilled in the art, including chiral high pressure liquidchromatography (HPLC) and the formation and crystallization of chiralsalts or prepared by asymmetric syntheses. See, for example, Jacques etal., Enantiomers, Racemates and Resolutions (Wiley Interscience, NewYork, 1981); Wilen, et al., Tetrahedron 33:2725 (1977); Eliel, E. L.Stereochemistry of Carbon Compounds (McGraw-Hill, N Y, 1962); Wilen, S.H. Tables of Resolving Agents and Optical Resolutions p. 268 (E. L.Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, Ind. 1972).

A wavy bond (

) at a chiral center in a chemical structure is used to denote compoundsof the invention that are optically pure, but whose optical rotation hasnot been determined. A straight bond at a chiral center indicates aracemic mixture although, as stated above, the invention also includesall possible isomeric forms of the racemate.

The terms “halo” and “halogen” as used herein refer to an atom selectedfrom fluorine (fluoro,—F), chlorine (chloro,—Cl), bromine (bromo,—Br),and iodine (iodo,—I).

The term “alkylene” refers to a bivalent alkyl group. An “alkylenechain” is a polymethylene group, i.e., —(CH₂)_(n)—, wherein n is apositive integer, preferably from 1 to 6, from 1 to 4, from 1 to 3, from1 to 2, or from 2 to 3. A substituted alkylene chain is a polymethylenegroup in which one or more methylene hydrogen atoms are replaced with asubstituent. Suitable substituents include those described below for asubstituted aliphatic group.

The term “alkyl,” as used herein, refers to a monovalent saturated,straight- or branched-chain hydrocarbon radical derived from analiphatic moiety containing between one and six carbon atoms by removalof a single hydrogen atom. In some embodiments, alkyl contains 1-5carbon atoms. In another embodiment, alkyl contains 1-4 carbon atoms. Instill other embodiments, alkyl contains 1-3 carbon atoms. In yet anotherembodiment, alkyl contains 1-2 carbons. Examples of alkyl radicalsinclude, but are not limited to, methyl, ethyl, n-propyl, isopropyl,n-butyl, iso-butyl, sec-butyl, sec-pentyl, iso-pentyl, tert-butyl,n-pentyl, neopentyl, n-hexyl, sec-hexyl, and the like.

As described herein, compounds of the invention may contain “optionallysubstituted” moieties. In general, the term “substituted”, whetherpreceded by the term “optionally” or not, means that one or morehydrogens of the designated moiety are replaced with a suitablesubstituent. Unless otherwise indicated, an “optionally substituted”group may have a suitable substituent at each substitutable position ofthe group, and when more than one position in any given structure may besubstituted with more than one substituent selected from a specifiedgroup, the substituent may be either the same or different at eachposition. Combinations of substituents envisioned under this inventionare preferably those that result in the formation of stable orchemically feasible compounds. The term “stable”, as used herein, refersto compounds that are not substantially altered when subjected toconditions to allow for their production, detection, and, in certainembodiments, their recovery, purification, and use for one or more ofthe purposes disclosed herein.

Suitable monovalent substituents on a substitutable carbon atom of an“optionally substituted” group are independently halogen;—(CH₂)₀₋₄R^(∘); —(CH₂)₀₋₄OR^(∘); —O—(CH₂)₀₋₄C(O)OR^(∘);—(CH₂)₀₋₄CH(OR^(∘))₂; —(CH₂)₀₋₄SR^(∘); —(CH₂)₀₋₄Ph, which may besubstituted with R^(∘); —(CH₂)₀₋₄O(CH₂)₀₋₁Ph which may be substitutedwith R^(∘); —CH═CHPh, which may be substituted with R^(∘); —NO₂; —CN;—N₃; —(CH₂)₀₋₄N(R^(∘))₂; —(CH₂)₀₋₄N(R^(∘))C(O)R^(∘); —N(R^(∘))C(S)R^(∘);—(CH₂)₀₋₄N(R^(∘))C(O)NR^(∘) ₂; —N(R^(∘))C(S)NR^(∘) ₂;—(CH₂)₀₋₄N(R^(∘))C(O)OR^(∘); —N(R^(∘))N(R^(∘))C(O)R^(∘);—N(R^(∘))N(R^(∘))C(O)NR^(∘) ₂; —N(R^(∘)) N(R^(∘))C(O)OR^(∘);—(CH₂)₀₋₄C(O)R; —C(S)R^(∘); —(CH₂)₀₋₄C(O)OR^(∘); —(CH₂)₀₋₄C(O)SR^(∘);—(CH₂)₀₋₄C(O)OSiR^(∘) ₃; —(CH₂)₀₋₄OC(O)R^(∘); —OC(O)(CH₂)₀₋₄SR—;—SC(S)SR^(∘); —(CH₂)₀₋₄SC(O)R^(∘); —(CH₂)₀₋₄C(O)NR^(∘) ₂; —C(S)NR^(∘) ₂;—C(S)SR^(∘); —SC(S)SR^(∘); —(CH₂)₀₋₄OC(O)NR^(∘) ₂; —C(O)N(OR^(∘)) R^(∘);—C(O)C(O)R^(∘); —C(O)CH₂C(O)R^(∘); —C(NOR^(∘))R^(∘); —(CH₂)₀₋₄SSR^(∘);—(CH₂)₀₋₄S(O)₂R^(∘); —(CH₂)₀₋₄S(O)₂OR^(∘); —(CH₂)₀₋₄OS(O)₂R^(∘);—S(O)₂NR^(∘) ₂; —(CH₂)₀₋₄S(O)R^(∘); —N(R^(∘))S(O)₂NR^(∘) ₂;—N(R^(∘))S(O)₂R^(∘); —N(OR^(∘))R^(∘); —C(NH)NR^(∘) ₂; —P(O)₂R^(∘);—P(O)R^(∘) ₂; —OP(O)R^(∘) ₂; —OP(O)(OR^(∘))₂; —SiR^(∘) ₃; —(C₁₋₄straight or branched alkylene)O—N(R^(∘))₂; or —(C₁₋₄ straight orbranched alkylene)C(O)O—N(R^(∘))₂, wherein each R^(∘) may be substitutedas defined below and is independently hydrogen, C₁₋₆ aliphatic, —CH₂Ph,—O(CH₂)₀₋₁Ph, or a 5-6-membered saturated, partially unsaturated, oraryl ring having 0-4 heteroatoms independently selected from nitrogen,oxygen, or sulfur, or, notwithstanding the definition above, twoindependent occurrences of R^(∘), taken together with their interveningatom(s), form a 3-12-membered saturated, partially unsaturated, or arylmono- or bicyclic ring having 0-4 heteroatoms independently selectedfrom nitrogen, oxygen, or sulfur, which may be substituted as definedbelow.

Suitable substituents on a substitutable nitrogen of an “optionallysubstituted” group include —R^(†), —NR^(†) ₂, —C(O)R^(†), —C(O)OR^(†),—C(O)C(O)R^(†), —C(O)CH₂C(O)R^(†), —S(O)₂R^(†), —S(O)₂NR^(†) ₂,—C(S)NR^(†) ₂, —C(NH)NR^(†) ₂, or —N(R^(†))S(O)₂R^(†); wherein eachR^(†) is independently hydrogen, C₁₋₆ aliphatic which may be substitutedas defined below, unsubstituted —OPh, or an unsubstituted 5-6-memberedsaturated, partially unsaturated, or aryl ring having 0-4 heteroatomsindependently selected from nitrogen, oxygen, or sulfur, or,notwithstanding the definition above, two independent occurrences ofR^(†), taken together with their intervening atom(s) form anunsubstituted 3-12-membered saturated, partially unsaturated, or arylmono- or bicyclic ring having 0-4 heteroatoms independently selectedfrom nitrogen, oxygen, or sulfur.

Suitable substituents on the aliphatic group of R^(†) are independentlyhalogen, —R^(•), -(haloR^(•)), —OH, —OR^(•), —O(haloR^(•)), —CN,—C(O)OH, —C(O)OR^(•), —NH₂, —NHR^(•), —NR^(•) ₂, or —NO₂, wherein eachR^(•) is unsubstituted or where preceded by “halo” is substituted onlywith one or more halogens, and is independently C₁₋₄aliphatic, —CH₂Ph,—O(CH₂)₀₋₁Ph, or a 5-6-membered saturated, partially unsaturated, oraryl ring having 0-4 heteroatoms independently selected from nitrogen,oxygen, or sulfur.

As used herein, the term “inhibitor” is defined as a compound that bindsto and/or inhibits a target S-adenosylmethionine (SAM) utilizing enzymewith measurable affinity. In certain embodiments, an inhibitor has anIC₅₀ and/or binding constant of less about 50 μM, less than about 1 μM,less than about 500 nM, less than about 100 nM, or less than about 10nM.

The terms “measurable affinity” and “measurably inhibit,” as usedherein, means a measurable change in activity of at least one SAMutilizing enzyme between a sample comprising a provided compound, orcomposition thereof, and at least one SAM dependent enzyme, and anequivalent sample comprising at least one SAM dependent enzyme, in theabsence of said compound, or composition thereof.

3. Description of Exemplary Compounds

In some embodiments of Formula II, R^(1a) is selected from —OCH₃, —CH₃,—OCHF₂, and —CH₂CH₃.

In some embodiments of Formula II, R^(4a) is selected from —CH₂OCH₃,—CH(CH₃)OCH₃, 4,4-difluorocyclohexyl, cyclopropyl,tetrayhyrdopyran-4-yl, 1-(t-butoxycarbonyl)-piperidin-4-yl,1-(isobutoxycarbonyl)-piperidin-4-yl,1-(isopropoxycarbonyl)-piperidin-4-yl, 1-(2-fluoroethyl)-piperidin-4-yl,1-(2,2-difluoroethyl)-piperidin-4-yl,1-(2,2,2-trifluoroethyl)-piperidin-4-yl,1-(2-hydroxyisobutyl)-piperidin-4-yl,1-(hydroxyisopropylcarbonyl)-piperidin-4-yl,1-(ethoxycarbonylmethyl)-piperidin-4-yl,1-(isopropylcarbonyl)-piperidin-4-yl, 1-methylpiperidin-4-yl,1-(methylsulfonyl)-piperidin-4-yl, 1-(ethylsulfonyl)-piperidin-4-yl,1-(isopropylsulfonyl)-piperidin-4-yl, 1-(phenyl)-piperidin-4-yl,1-(oxetan-3-yl)piperidin-4-yl, 1-(pyridin-2-yl)-piperidin-4-yl, and1-(pyrimidin-2-yl)-piperidin-4-yl.

In some embodiments of Formula II, R¹³ is selected from hydrogen,chloro, fluoro, —OCH(CH₃)₂, phenyl, and pyridin-2-yl.

Exemplary compounds of Formula II are set forth in FIG. 1. In some casestwo (or more) of the compounds in FIG. 1 having one (or more) wavy bondswill have the exact same structure. Because the wavy bond represents achiral center of undetermined optical rotation, such compounds will beunderstood to be separate and distinct optical isomers of one another.FIG. 1 is annotated to indicate those sets of two or more compounds thathave the same depicted structure, but are of different stereochemistry.

4. Uses, Formulation and Administration Pharmaceutically AcceptableCompositions

According to another embodiment, the invention provides a compositioncomprising a compound of this invention or a pharmaceutically acceptablederivative thereof and a pharmaceutically acceptable carrier, adjuvant,or vehicle. The amount of compound in compositions of this invention issuch that is effective to measurably modulate a histone methyl modifyingenzyme, or a mutant thereof, in a biological sample or in a patient. Incertain embodiments, the amount of compound in compositions of thisinvention is such that is effective to measurably modulate a histonemethyl modifying enzyme, or a mutant thereof, in a biological sample orin a patient.

In certain embodiments, a composition of this invention is formulatedfor administration to a patient in need of such composition. In someembodiments, a composition of this invention is formulated for oraladministration to a patient.

The term “patient,” as used herein, means an animal, preferably amammal, and most preferably a human.

The term “pharmaceutically acceptable carrier, adjuvant, or vehicle”refers to a non-toxic carrier, adjuvant, or vehicle that does notdestroy the pharmacological activity of the compound with which it isformulated. Pharmaceutically acceptable carriers, adjuvants or vehiclesthat may be used in the compositions of this invention include, but arenot limited to, ion exchangers, alumina, aluminum stearate, lecithin,serum proteins, such as human serum albumin, buffer substances such asphosphates, glycine, sorbic acid, potassium sorbate, partial glyceridemixtures of saturated vegetable fatty acids, water, salts orelectrolytes, such as protamine sulfate, disodium hydrogen phosphate,potassium hydrogen phosphate, sodium chloride, zinc salts, colloidalsilica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-basedsubstances, polyethylene glycol, sodium carboxymethylcellulose,polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers,polyethylene glycol and wool fat.

A “pharmaceutically acceptable derivative” means any non-toxic salt,ester, salt of an ester or other derivative of a compound of thisinvention that, upon administration to a recipient, is capable ofproviding, either directly or indirectly, a compound of this inventionor an inhibitorily active metabolite or residue thereof.

Compositions of the present invention may be administered orally,parenterally, by inhalation spray, topically, rectally, nasally,buccally, vaginally or via an implanted reservoir. The term “parenteral”as used herein includes subcutaneous, intravenous, intramuscular,intra-articular, intra-synovial, intrasternal, intrathecal,intrahepatic, intralesional and intracranial injection or infusiontechniques. Preferably, the compositions are administered orally,intraperitoneally or intravenously. Sterile injectable forms of thecompositions of this invention may be aqueous or oleaginous suspension.These suspensions may be formulated according to techniques known in theart using suitable dispersing or wetting agents and suspending agents.The sterile injectable preparation may also be a sterile injectablesolution or suspension in a non-toxic parenterally acceptable diluent orsolvent, for example as a solution in 1,3-butanediol. Among theacceptable vehicles and solvents that may be employed are water,Ringer's solution and isotonic sodium chloride solution. In addition,sterile, fixed oils are conventionally employed as a solvent orsuspending medium.

For this purpose, any bland fixed oil may be employed includingsynthetic mono- or di-glycerides. Fatty acids, such as oleic acid andits glyceride derivatives are useful in the preparation of injectables,as are natural pharmaceutically-acceptable oils, such as olive oil orcastor oil, especially in their polyoxyethylated versions. These oilsolutions or suspensions may also contain a long-chain alcohol diluentor dispersant, such as carboxymethyl cellulose or similar dispersingagents that are commonly used in the formulation of pharmaceuticallyacceptable dosage forms including emulsions and suspensions. Othercommonly used surfactants, such as Tweens, Spans and other emulsifyingagents or bioavailability enhancers which are commonly used in themanufacture of pharmaceutically acceptable solid, liquid, or otherdosage forms may also be used for the purposes of formulation.

Pharmaceutically acceptable compositions of this invention may be orallyadministered in any orally acceptable dosage form including, but notlimited to, capsules, tablets, aqueous suspensions or solutions. In thecase of tablets for oral use, carriers commonly used include lactose andcorn starch. Lubricating agents, such as magnesium stearate, are alsotypically added. For oral administration in a capsule form, usefuldiluents include lactose and dried cornstarch. When aqueous suspensionsare required for oral use, the active ingredient is combined withemulsifying and suspending agents. If desired, certain sweetening,flavoring or coloring agents may also be added.

Alternatively, pharmaceutically acceptable compositions of thisinvention may be administered in the form of suppositories for rectaladministration. These can be prepared by mixing the agent with asuitable non-irritating excipient that is solid at room temperature butliquid at rectal temperature and therefore will melt in the rectum torelease the drug. Such materials include cocoa butter, beeswax andpolyethylene glycols.

Pharmaceutically acceptable compositions of this invention may also beadministered topically, especially when the target of treatment includesareas or organs readily accessible by topical application, includingdiseases of the eye, the skin, or the lower intestinal tract. Suitabletopical formulations are readily prepared for each of these areas ororgans.

Topical application for the lower intestinal tract can be effected in arectal suppository formulation (see above) or in a suitable enemaformulation. Topically-transdermal patches may also be used.

For topical applications, provided pharmaceutically acceptablecompositions may be formulated in a suitable ointment containing theactive component suspended or dissolved in one or more carriers.Carriers for topical administration of compounds of this inventioninclude, but are not limited to, mineral oil, liquid petrolatum, whitepetrolatum, propylene glycol, polyoxyethylene, polyoxypropylenecompound, emulsifying wax and water. Alternatively, providedpharmaceutically acceptable compositions can be formulated in a suitablelotion or cream containing the active components suspended or dissolvedin one or more pharmaceutically acceptable carriers. Suitable carriersinclude, but are not limited to, mineral oil, sorbitan monostearate,polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol,benzyl alcohol and water.

For ophthalmic use, provided pharmaceutically acceptable compositionsmay be formulated as micronized suspensions in isotonic, pH adjustedsterile saline, or, preferably, as solutions in isotonic, pH adjustedsterile saline, either with or without a preservative such asbenzylalkonium chloride. Alternatively, for ophthalmic uses, thepharmaceutically acceptable compositions may be formulated in anointment such as petrolatum.

Pharmaceutically acceptable compositions of this invention may also beadministered by nasal aerosol or inhalation. Such compositions areprepared according to techniques well-known in the art of pharmaceuticalformulation and may be prepared as solutions in saline, employing benzylalcohol or other suitable preservatives, absorption promoters to enhancebioavailability, fluorocarbons, and/or other conventional solubilizingor dispersing agents.

Most preferably, pharmaceutically acceptable compositions of thisinvention are formulated for oral administration. Such formulations maybe administered with or without food. In some embodiments,pharmaceutically acceptable compositions of this invention areadministered without food. In other embodiments, pharmaceuticallyacceptable compositions of this invention are administered with food.

The amount of compounds of the present invention that may be combinedwith the carrier materials to produce a composition in a single dosageform will vary depending upon the host treated and the particular modeof administration. Preferably, provided compositions should beformulated so that a dosage of between 0.01-100 mg/kg body weight/day ofthe inhibitor can be administered to a patient receiving thesecompositions.

It should also be understood that a specific dosage and treatmentregimen for any particular patient will depend upon a variety offactors, including the activity of the specific compound employed, theage, body weight, general health, sex, diet, time of administration,rate of excretion, drug combination, and the judgment of the treatingphysician and the severity of the particular disease being treated. Theamount of a compound of the present invention in the composition willalso depend upon the particular compound in the composition.

Uses of Compounds and Pharmaceutically Acceptable Compositions

Compounds and compositions described herein are generally useful for themodulating of activity of one or more enzymes involved in epigeneticregulation.

Epigenetics is the study of heritable changes in gene expression causedby mechanisms other than changes in the underlying DNA sequence.Molecular mechanisms that play a role in epigenetic regulation includeDNA methylation and chromatin/histone modifications. Histonemethylation, in particular, is critical in many epigenetic phenomena.

Chromatin, the organized assemblage of nuclear DNA and histone proteins,is the basis for a multitude of vital nuclear processes includingregulation of transcription, replication, DNA-damage repair andprogression through the cell cycle. A number of factors, such aschromatin-modifying enzymes, have been identified that play an importantrole in maintaining the dynamic equilibrium of chromatin (Margueron, etal. (2005) Curr. Opin. Genet. Dev. 15:163-176).

Histones are the chief protein components of chromatin. They act asspools around which DNA winds, and they play a role in gene regulation.There are a total of six classes of histones (H1, H2A, H2B, H3, H4, andH5) organized into two super classes: core histones (H2A, H2B, H3, andH4) and linker histones (H1 and H5). The basic unit of chromatin is thenucleosome, which consists of about 147 base pairs of DNA wrapped aroundthe histone octamer, consisting of two copies each of the core histonesH2A, H2B, H3, and H4 (Luger, et al. (1997) Nature 389:251-260).

Histones, particularly residues of the amino termini of histones H3 andH4 and the amino and carboxyl termini of histones H2A, H2B and H1, aresusceptible to a variety of post-translational modifications includingacetylation, methylation, phosphorylation, ribosylation, sumoylation,ubiquitination, citrullination, deimination, and biotinylation. The coreof histones H2A and H3 can also be modified. Histone modifications areintegral to diverse biological processes such as gene regulation, DNArepair, and chromosome condensation.

The present disclosure provides compounds and compositions formodulating activity of histone methyl modifying enzymes. Histone methylmodifying enzymes are key regulators of cellular and developmentalprocesses. Histone methyl modifying enzymes may be characterized aseither histone methyl transferases or histone demethylases. Histonedemethylase enzymes have modules that mediate binding to methylatedresidues. For example, multiple demethylases contain a Tudor domain(e.g., JMJD2C/GASC1) or a PHD domain (e.g., JARID1C/SMCX, PHF8).

The lysine specificities of many histone methyltransferases have beencharacterized. For example SET7/9, SMYD3, and MLL1-5 are specific forH3K4. SUV39H1, DIM-5, and G9a are specific for H3K9. SET8 is specificfor H4K20.

DOT1 is an example of a non-SET domain containing histone methylase.DOT1 methylates H3 on lysine 79.

Just as histone methylases have been shown to regulate transcriptionalactivity, chromatin structure, and gene silencing, demethylases havealso been discovered which impact gene expression. LSD1 was the firsthistone lysine demethylase to be characterized. This enzyme displayshomology to FAD-dependent amine oxidases and acts as a transcriptionalcorepressor of neuronal genes (Shi et al., Cell 119:941-953, 2004).Additional demethylases defining separate demethylase families have beendiscovered, including JHDM1 (or KDM2), JHDM2 (or KDM3), JMJD2 (or KDM4),JARID (or KDM5), JMJD3 (or KDM6), and JMJD6 families (Lan et al., Curr.Opin. Cell Biol. 20(3):316-325, 2008).

Demethylases act on specific lysine residues within substrate sequencesand discriminate between the degree of methylation present on a givenresidue. For example, LSD1 removes mono- or dimethyl-groups from H3K4.Members of the JARID1A-D family remove trimethyl groups from H3K4. UTXand JMJD3 demethylate H3K27, counteracting effects of EZH2 methylaseactivity. Substrate specificities of other demethylases have beencharacterized (see Shi, Nat. Rev. 8:829-833, 2007).

One class of histone methylases is characterized by the presence of aSET domain, named after proteins that share the domain, Su(var)3-9,enhancer of zeste [E(Z)], and trithorax. A SET domain includes about 130amino acids. SET domain-containing methylase families include SUV39H1,SET1, SET2, EZH2, RIZ1, SMYD3, SUV4-20H1, SET7/9, and PR-SET7/SET8families (reviewed in Dillon et al., Genome Biol. 6:227, 2005). Membersof a family typically include similar sequence motifs in the vicinity ofand within the SET domain. The human genome encodes over 50 SETdomain-containing histone protein methylases, any of which can be usedin an assay described herein.

EZH2 is an example of a human SET-domain containing methylase. EZH2associates with EED (Embryonic Ectoderm Development) and SUZ12(suppressor of zeste 12 homolog) to form a complex known as PRC2(Polycomb Group Repressive Complex 2) having the ability totri-methylate histone H3 at lysine 27 (Cao and Zhang, Mol. Cell15:57-67, 2004). PRC2 complexes can also include RBAP46 and RBAP48subunits.

The oncogenic activities of EZH2 have been shown by a number of studies.In cell line experiments, over-expression of EZH2 induces cell invasion,growth in soft agar, and motility while knockdown of EZH2 inhibits cellproliferation and cell invasion (Kleer et al., 2003, Proc. Nat. Acad.Sci. USA 100:11606-11611; Varambally et al., (2002), “The polycomb groupprotein EZH2 is involved in progression of prostate cancer,” Nature 419,624-629). It has been shown that EZH2 represses the expression ofseveral tumor suppressors, including E-cadherin, DAB2IP and RUNX3 amongothers. In xenograft models, EZH2 knockdown inhibits tumor growth andmetastasis. Recently, it has been shown that down modulation of EZH2 inmurine models blocks prostate cancer metastasis (Min et al., “Anoncogene-tumor suppressor cascade drives metastatic prostate cancer bycoordinately activating Ras and nuclear factor-kappaB,” Nat Med. 2010March; 16(3):286-94). EZH2 overexpression is associated withaggressiveness of certain cancers such as breast cancer (Kleer et al.,Proc. Nat. Acad. Sci. USA 100:11606-11611, 2003). Recent studies alsosuggest that prostate cancer specific oncogenic fusion gene TMPRSS2-ERGinduces repressive epigenetic programs via direct activation of EZH2 (Yuet al., “An Integrated Network of Androgen Receptor, Polycomb, andTMPRSS2-ERG Gene Fusions in Prostate Cancer Progression,” Cancer Cell.2010 May 18; 17(5):443-454).

In some embodiments, compounds of the present invention modulate theactivity of one or more enzymes involved in epigenetic regulation. Insome embodiments, compounds of the present invention modulate theactivity of a histone methyl modifying enzyme, or a mutant thereof. Insome embodiments, compounds of the present invention modulate EZH2activity. In some embodiments, compounds of the present inventiondown-regulate or suppress the activity of EZH2. In some embodiments,compounds of the present invention are antagonists of EZH2 activity.

In some embodiments, compounds and compositions of the present inventionare useful in treating diseases and/or disorders associated with ahistone methyl modifying enzyme. Accordingly, in some embodiments, thepresent invention provides a method of modulating a disease and/ordisorder associated with a histone methyl modifying enzyme. In someembodiments, the present invention provides a method of treating asubject suffering from a disease and/or disorder associated with ahistone methyl modifying enzyme comprising the step of administering acompound or composition of Formula II.

In some embodiments, compounds and compositions of the present inventionare useful in treating diseases and/or disorders associated withoverexpression of EZH2. In some embodiments, the present inventionprovides a method of treating a subject suffering from a disease and/ordisorder associated with overexpression of EZH2 comprising the step ofadministering a compound or composition of Formula II. In someembodiments, the above method additionally comprises the preliminarystep of determining if the subject is overexpressing EZH2.

In some embodiments, compounds and compositions of the present inventionare useful in treating diseases and/or disorders associated withcellular proliferation. In some embodiments, compounds and compositionsof the present invention are useful in treating diseases and/ordisorders associated with misregulation of cell cycle or DNA repair. Insome embodiments, compounds and compositions of the present inventionare useful in treating cancer. Exemplary types of cancer include breastcancer, prostate cancer, colon cancer, renal cell carcinoma,glioblastoma multiforme cancer, bladder cancer, melanoma, bronchialcancer, lymphoma and liver cancer.

The study of EZH2 deletions, missense and frameshift mutations suggestthat EZH2 functions as a tumor suppressor in blood disorders such asmyelodysplastic syndromes (MDS) and myeloid malignancies (Ernst et al.,Nat Genet. 2010 August; 42(8):722-6; Nikoloski et al., Nat Genet. 2010August; 42(8):665-7). Accordingly, in some embodiments, compounds andcompositions of the present invention are useful in treating diseasesand/or disorders associated with the presence of a mutant form of EZH2.In some embodiments, compounds and compositions of the present inventionare useful in treating diseases and/or disorders associated with thepresence of Y641N EZH2. In some embodiment, the disease or disorderassociated with the presence of a mutant form of EZH2 is a human B celllymphoma. In some embodiments, the disease and/or disorder associatedwith the presence of Y641N EZH2 is follicular lymphoma or diffuselarge-B-cell lymphoma. In some embodiments, compounds or compositions ofthe present invention are useful in treating blood disorders, such asmyelodysplastic syndromes, leukemia, anemia and cytopenia. Sneeringer etal., “Coordinated activities of wild-type plus mutant EZH2 drivetumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27)in human B-cell lymphomas,” Proceedings of the National Academy ofSciences, PNAS Early Edition published ahead of print on Nov. 15, 2010.

In some embodiments, the present invention provides a method of reducingthe activity of EZH2 in a subject comprising the step of administering acompound or composition of Formula II. In some embodiments, the presentinvention provides a method of reducing the activity of wide-type EZH2in a subject comprising the step of administering a compound orcomposition of Formula II. In some embodiments, the present inventionprovides a method of reducing the activity of a mutant form of EZH2 in asubject comprising the step of administering a compound or compositionof Formula II. In some embodiments, the present invention provides amethod of reducing the activity of a mutant form of EZH2 in a subjectcomprising the step of administering a compound or composition ofFormula II, wherein the mutant form of EZH2 is Y641N EZH2. In someembodiments, the present invention provides a method of treating asubject suffering from a disease and/or disorder associated with EZH2comprising the step of administering a compound or composition ofFormula II. In some embodiments, the present invention provides a methodof treating a subject suffering from a disease and/or disorderassociated with wide-type EZH2 comprising the step of administering acompound or composition of Formula II. In some embodiments, the presentinvention provides a method of treating a subject suffering from adisease and/or disorder associated with a mutant form of EZH2 comprisingthe step of administering a compound or composition of Formula II. Insome embodiments, the present invention provides a method of treating asubject suffering from a disease and/or disorder associated with amutant form of EZH2 comprising the step of administering a compound orcomposition of Formula II, wherein the mutant form of EZH2 is Y641NEZH2. In some embodiments, the above method additionally comprises thepreliminary step of determining if the subject is expressing a mutantform of EZH2, such as Y641N EZH2. In some embodiments, the presentinvention provides a method of reducing the activity of a mutant form ofEZH2, such as Y641N EZH2, in a subject in need thereof comprising thestep of administering a compound or composition of Formula II. In someembodiments, the present invention provides a method of treating asubject suffering from a disease and/or disorder associated with amutant form of EZH2 comprising the step of administering a compound orcomposition of Formula II. In some embodiments, the above methodadditionally comprises the preliminary step of determining if thesubject is expressing a mutant form of EZH2, such as Y641N EZH2. In someembodiments, that determination is made by determining if the subjecthas increased levels of histone H3 Lys-27-specific trimethylation(H3K27me3), as compared to a subject known not to express a mutant formof EZH2.

Equivalents

The representative examples that follow are intended to help illustratethe invention, and are not intended to, nor should they be construed to,limit the scope of the invention. Indeed, various modifications of theinvention and many further embodiments thereof, in addition to thoseshown and described herein, will become apparent to those skilled in theart from the full contents of this document, including the examples thatfollow and the references to the scientific and patent literature citedherein. It should further be appreciated that the contents of thosecited references are incorporated herein by reference to help illustratethe state of the art.

It will be appreciated that for compound preparations described herein,when reverse phase HPLC is used to purify a compound, a compound mayexist as an acid addition salt. In some embodiments, a compound mayexist as a formic acid or mono-, di-, or tri-trifluoroacetic acid salt.

It will further be appreciated that the present invention contemplatesindividual compounds described herein. Where individual compoundsexemplified are isolated and/or characterized as a salt, for example, asa trifluoroacetic acid salt, the present invention contemplates a freebase of the salt, as well as other pharmaceutically acceptable salts ofthe free base.

The following examples contain important additional information,exemplification and guidance that can be adapted to the practice of thisinvention in its various embodiments and the equivalents thereof.

Procedures for preparing the compounds exemplified below, as well asadditional compounds/intermediates in the synthetic schemes can be foundin International Application No. PCT/US2013/025639, the contents ofwhich are incorporated herein by reference.

EXAMPLES

As depicted in the Examples below, in certain exemplary embodiments,compounds are prepared according to the following general procedures. Itwill be appreciated that, although the synthetic methods and Schemesdepict the synthesis of certain compounds of the present invention, thefollowing methods and other methods known to one of ordinary skill inthe art can be applied to all compounds and subclasses and species ofeach of these compounds, as described herein.

Unless otherwise noted, all solvents, chemicals, and reagents wereobtained commercially and used without purification. The ¹H NMR spectrawere obtained in CDCl₃, d₆-DMSO, CD₃OD, or d₆-acetone at 25° C. at 300MHz on an OXFORD (Varian) with chemical shift (δ, ppm) reported relativeto TMS as an internal standard. HPLC-MS chromatograms and spectra wereobtained with Shimadzu LC-MS-2020 system. Chiral analysis andpurification were obtained with Yilite P270.

Example 1 Synthesis of Compounds 327 and 346 and Related Compounds andIntermediates

The title compounds of this Example and other related compounds wereprepared according to the following general scheme. In addition, whereindicated, modifications of this scheme are disclosed for the synthesisof still additional related compounds of the invention and intermediatesthereof.

Step 1: (S,E)-tert-butyl4-(((tert-butylsulfinyl)imino)methyl)piperidine-1-carboxylate:(S)-2-methylpropane-2-sulfinamide

To a round bottomed flask charged with a magnetic stir bar was added(S)-2-methylpropane-2-sulfinamide (20.46 g, 169 mmol), tert-butyl4-formylpiperidine-1-carboxylate (30 g, 141 mmol), DCM (300 mL), andTi(OEt)₄ (59.0 ml, 281 mmol). The solution was stirred at roomtemperature for 3 h before it was quenched with brine (80 mL). Thesolution was stirred for 30 minutes before filtering. The filter cakewas washed with DCM and the filtrate was placed in a separatory funneland washed with water. The organics layer was dried over Na₂SO₄,filtered, and concentrated in vacuo. The crude residue solidified to thetitle compound (29 g, 92 mmol, 65.1% yield) m/z 217.

The intermediate shown in the following table was prepared according tothe general procedure outlined in Step 1 using the appropriate startingmaterials and modifications.

Name Structure m/z (S,E)-2-methyl-N-((tetrahydro- 2H-pyran-4-yl)methylene)propane- 2-sulfinamide

Step 2: Tert-butyl 4-((S)-1-((R orS)-1,1-dimethylethylsulfinamido)ethyl)piperidine-1-carboxylate

To a round bottomed flask charged with a magnetic stir bar was added(S,E)-tert-butyl4-((tert-butylsulfinylimino)methyl)piperidine-1-carboxylate (36.4 g, 115mmol), DCM (400 mL), and the solution was cooled to 0° C. in an ice bathwith stirring. To this solution was added MeMgBr (77 ml, 230 mmol) (3Min diethyl ether) and the reaction stirred for 4 h while warming to roomtemperature. The reaction was carefully quenched via the addition ofsaturated aqueous NH₄Cl. The solid were broken up by the addition of 1NHCl. The layers were separated and the aqueous phase was extracted withDCM. The combined organics phase was dried over Na₂SO₄, filtered, andconcentrated in vacuo to afford the title compound (29 g, >9:1 dr) whichis used without further purification in the next step.

The intermediate shown in the following table was prepared according tothe general procedure outlined in Step 2 using the appropriate startingmaterials and modifications.

Name Structure m/z (S)-2-methyl-N-((R or S)-1- (tetrahydro-2H-pyran-4-yl)ethyl)propane-2-sulfinamide

234

Step 3: (R or S)-tert-butyl 4-(1-aminoethyl)piperidine-1-carboxylate

To a 1 L round bottomed flask charged with a magnetic stir bar was addedcrude tert-butyl4-((S)-1-((S)-1,1-dimethylethylsulfinamido)ethyl)piperidine-1-carboxylate(29 g) was taken up in MeOH (200 mL) before addition of a 4 N solutionof HCl in 1,4-dioxane (24.06 ml, 96 mmol). The resulting solution wasthen stirred at room temperature for 1 h at rt. The methanol was thenremoved in vacuo to afford viscous oil which was treated with sat'daqueous NaHCO₃ (˜500 mL) and extracted with ethyl acetate (2×500 mL).This organic phase was combined, dried with MgSO₄, filtered, and solventwas then removed in vacuo affording the title compound (22 g) which wasused without further purification.

The intermediate shown in the following table was prepared according tothe general procedure outlined in Step 3 using the appropriate startingmaterials.

Name Structure m/z (R or S)-1-(tetrahydro-2H-pyran-4-yl)ethanamine

130

Step 4: Methyl 2-(2-bromophenyl)-3-oxobutanoate

A round bottomed flask was charged with a magnetic stir bar and methyl2-(2-bromophenyl)acetate (25 g, 109 mmol) and THF (50 mL). This solutionwas cooled to −78° C. before drop wise addition of a 1M solution ofLiHMDS in THF (218 ml, 218 mmol). The reaction was stirred for 30 min at−78° C. before addition of 1-(1H-imidazol-1-yl)ethanone (14.42 g, 131mmol) dissolved in a mixture of THF:DMF (112 mL THF, 24 mL DMF). Thesolution was stirred for 1 h before quenching with sat'd aqueous NH₄Cl(˜250 mL) and diluting with EtOAc. The layers were separated and theaqueous phase was extracted with EtOAc (˜2×250 mL). The combined organicextract was washed with brine, dried over Na₂SO₄, filtered, andconcentrated in vacuo. The crude residue was purified via silica gelchromatography using an eluent of ethyl acetate/hexanes (10:1) to affordmethyl 2-(2-bromophenyl)-3-oxobutanoate (32.5 g, 102 mmol, 93% yield).

The intermediates shown in the following table were prepared accordingto the general procedure outlined in Step 4 using the appropriatestarting materials.

Name Structure m/z methyl 2-(2-bromo-4- chlorophenyl)-3-oxobutanoate

304 methyl 2-(2-bromo-4- methoxyphenyl)-3- oxobutanoate

302 methyl 2-(2-bromo-4- fluorophenyl)-3-oxobutanoate

289

Step 5: (R or S, E and Z)-tert-butyl4-(1-(3-(2-bromophenyl)-4-methoxy-4-oxobut-2-en-2-ylamino)ethyl)piperidine-1-carboxylate

To a round bottomed flask was added (R or S)-tert-butyl4-(1-aminoethyl)piperidine-1-carboxylate (9.35 g, 40.9 mmol), EtOH (75mL), and methyl 2-(2-bromophenyl)-3-oxobutanoate (7.40 g, 27.3 mmol)(from Step 4). To this solution was added AcOH (1.563 ml, 27.3 mmol) andthe reaction was heated overnight at 85° C. before cooling to roomtemperature and concentrating. The crude residue was purified via silicagel chromatography (330 g, 100% hexanes to 25% EA in hexanes) to affordthe title compound (6.45 g, 13.40 mmol, 49.1% yield).

The intermediates shown in the following table were prepared accordingto the general procedure outlined in Step 5 using the appropriatestarting materials.

Name Structure m/z (R or S,Z)-methyl 2-(2- bromophenyl)-3-((1-(tetrahydro-2H-pyran-4- yl)ethyl)amino)but-2- enoate

383 (R or S,Z)-methyl 2-(2- bromo-4-chlorophenyl)-3-((1-(tetrahydro-2H-pyran- 4-yl)ethyl)amino)but-2- enoate

417 (R or S,Z)-methyl 2-(2- bromo-4-chlorophenyl)-3-((1-(tetrahydro-2H-pyran- 4-yl)ethyl)amino)but-2- enoate

417 (R or S,Z)-methyl 2-(2- bromo-4-fluorophenyl)-3-((1-(tetrahydro-2H-pyran- 4-yl)ethyl)amino)but-2- enoate

401

Step 6: (R or S)-methyl1-(1-(1-(tert-butoxycarbonyl)piperidin-4-yl)ethyl)-2-methyl-1H-indole-3-carboxylate

A 250 mL round bottom flask was charged with a magnetic stir bar, (R orS,Z)-tert-butyl4-(1-(3-(2-bromophenyl)-4-methoxy-4-oxobut-2-en-2-ylamino)ethyl)piperidine-1-carboxylate(3.33 g, 6.92 mmol), RuPhos Pre-catalyst II(Methanesulfonato(2-dicyclohexylphosphino-2′,6′-di-i-propoxy-1,1′-biphenyl)(2-amino-1,1′-biphenyl-2-yl)palladium(II)) (0.463 g, 0.553 mmol),dicyclohexyl(2′,6′-diisopropoxybiphenyl-2-yl)phosphine (0.387 g, 0.830mmol), anhydrous 1,4-dioxane (27.7 ml, 6.92 mmol), and sodium methoxide(0.561 g, 10.38 mmol). The reaction mixture was purged and back-filledwith nitrogen and heated to 100° C. with stirring overnight before beingallowed to cool to rt. The reaction was diluted with ethyl acetate (˜100ml) and the mixture was filtered through a bed of diatomaceous earth.The filtrate was pre-absorbed onto silica gel (˜30 g) and purified viasilica gel chromatography (120 g) using ethyl acetate/hexanes (1:1) aseluent to afford the title compound (2.01 g, 4.77 mmol, 68.9% yield).

The intermediates shown in the following table were prepared accordingto the general procedure outlined in Step 6 using the appropriatestarting materials.

Name Structure m/z (R or S)-methyl 2-methyl-1- (1-(tetrahydro-2H-pyran-4-yl)ethyl)-1H-indole-3- carboxylate

302 (R or S)-methyl 6-chloro-2- methyl-1-(1-(tetrahydro-2H-pyran-4-yl)ethyl)-1H- indole-3-carboxylate

337 (R or S)-methyl 6-methoxy- 2-methyl-1-(1-(tetrahydro-2H-pyran-4-yl)ethyl)- 1H-indole-3-carboxylate

332 (R or S)-methyl 6-fluoro- 2-methyl-1-(1-(tetrahydro-2H-pyran-4-yl)ethyl)-1H- indole-3-carboxylate

320

Step 7: (R orS)-2-methyl-1-(1-(tetrahydro-2H-pyran-4-yl)ethyl)-1H-indole-3-carboxylicacid

A 1 L round bottom flask was charged with a magnetic stir bar, (R orS)-methyl2-methyl-1-(1-(tetrahydro-2H-pyran-4-yl)ethyl)-1H-indole-3-carboxylate(11.60 g, 38.5 mmol), ethanol (96 ml, 38.5 mmol), and 6 N aqueous NaOH(64.1 ml, 385 mmol). The flask was fitted with a reflux condenser andheated to reflux for 6 h before being allowed to cool to rt. Thevolatiles were removed in vacuo and the resulting mixture was pouredinto 10% HCl (˜300 mL). A precipitate formed which was collected viavacuum filtration using a Buchner funnel. The filter cake was rinsedwith an additional portion of water (˜200 mL), collected, and driedunder vacuum to afford the title compound (10.87 g, 35.9 mmol, 93%yield) as an off-white solid.

The intermediates shown in the following table were prepared accordingto the general procedure outlined in Step 7 using the appropriatestarting materials.

Name Structure m/z (R or S)-2-methyl-1-(1- (tetrahydro-2H-pyran-4-yl)ethyl)-1H-indole- 3-carboxylic acid

287 (R or S)-6-chloro-2- methyl-1-(1- (tetrahydro-2H-pyran-4-yl)ethyl)-1H-indole- 3-carboxylic acid

321 (R or S)-6-methoxy-2- methyl-1-(1- (tetrahydro-2H-pyran-4-yl)ethyl)-1H-indole- 3-carboxylic acid

317 (R or S)-6-fluoro-2- methyl-1-(1- (tetrahydro-2H-pyran-4-yl)ethyl)-1H-indole- 3-carboxylic acid

306 (R or S)-2-methyl-6- (pyridin-3-yl)-1-(1- (tetrahydro-2H-pyran-4-yl)ethyl)-1H-indole- 3-carboxylic acid

365

Step 8: (R or S)-tert-butyl4-(1-(3-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methylcarbamoyl)-2-methyl-1H-indol-1-yl)ethyl)piperidine-1-carboxylate(Compound 327)

A 250 mL round bottom flask was charged with a magnetic stir bar, (R orS)-1-(1-(1-(tert-butoxycarbonyl)piperidin-4-yl)ethyl)-2-methyl-1H-indole-3-carboxylicacid (1.950 g, 5.05 mmol),3-(aminomethyl)-4-methoxy-6-methylpyridin-2(1H)-one hydrochloride (2.065g, 10.09 mmol), DMF (25.2 ml, 5.05 mmol), Hunig's base (3.52 ml, 20.18mmol). The reaction mixture was cooled to 0° C. and COMU (2.16 g, 5.05mmol) was added. The reaction was allowed to stir overnight to roomtemperature. The reaction mixture was diluted with water and extractedwith EtOAc. The combined organic extract was washed with brine, driedwith MgSO₄, filtered and conc. in vacuo to afford the crude materialwhich was purified via silica gel chromatography (120 g) usingMeOH/ethyl acetate (1:5) as eluent to afford the title compound (1.86 g,3.29 mmol, 65.3% yield). LCMS 537 (M+1)⁺ ¹ H NMR (400 MHz, DMSO-d₆)δ=11.83-11.71 (m, 1H), 7.80 (br. s., 1H), 7.73 (d, J=7.6 Hz, 1H), 7.62(d, J=7.8 Hz, 1H), 7.06 (td, J=7.1, 14.4 Hz, 2H), 6.21 (s, 1H), 4.32(br. s., 2H), 4.16 (br. s., 1H), 4.02 (br. s., 1H), 3.85 (s, 3H), 3.75(br. s., 1H), 2.70 (br. s., 1H), 2.58 (s, 3H), 2.37 (br. s., 1H), 2.21(s, 3H), 1.90 (d, J=12.9 Hz, 1H), 1.53 (d, J=6.9 Hz, 3H), 1.35 (s, 10H),1.21 (br. s., 1H), 0.89 (d, J=8.7 Hz, 1H), 0.67 (d, J=11.8 Hz, 1H).

The compounds shown in the following table were prepared according tothe general procedure outlined in Step 8 using the appropriate startingmaterials. The structures of the compounds are shown in FIG. 1.

Compound Number Name ¹H NMR m/z 435 (R or S)-tert-butyl 4-(1-(3-(((4,6-521 dimethyl-2-oxo-1,2- dihydropyridin-3- yl)methyl)carbamoyl)-2-methyl-1H-indol-1-yl)ethyl)piperidine-1- carboxylate 436 (R or S)-tert-butyl4-(1-(3-(((4- 573 (difluoromethoxy)-6-methyl-2-oxo-1,2-dihydropyridin-3- yl)methyl)carbamoyl)-2-methyl-1H-indol-1-yl)ethyl)piperidine-1- carboxylate 437 (R or S)-tert-butyl4-(1-(3-(((4- 535 ethyl-6-methyl-2-oxo-1,2- dihydropyridin-3-yl)methyl)carbamoyl)-2-methyl- 1H-indol-1-yl)ethyl)piperidine-1-carboxylate 298 (R or S)-N-((4-methoxy-6- (400 MHz, DMSO-d₆) δ 11.60 (s,438 methyl-2-oxo-1,2-dihydropyridin- 1H), 7.73-7.62 (m, 3H), 7.60 (d,3-yl)methyl)-2-methyl-1-(1- 2H) 7.07-7.05 (m, 2H), 6.15 (s, 1H)(tetrahydro-2H-pyran-4-yl)ethyl)- 4.33 (s, 1H), 4.21-4.11 (m, 1H),1H-indole-3-carboxamide 3.92 (br. d., 1H), 3.65 (d, 1H), 3.34- 3.32 (m,1H), 3.02 (t, 1H), 2.61 (s, 3H), 2.48-2.44 (m, 1H), 2.20 (s, 3H),1.84-1.81 (m, 1H), 1.54 (d, 3H), 1.40-1.38 (m, 12H), 1.25-1.22 (m, 1H),1.08-1.04 (m, 1H), 0.86 (br. s., 1H), 0.58 (br. d., 1H) 300 (R orS)-6-fluoro-N-((4-methoxy- (400 MHz, DMSO-d₆) δ = 11.57 4566-methyl-2-oxo-1,2- (br. s., 1 H), 7.75-7.67 (m, 2 H),dihydropyridin-3-yl)methyl)-2- 7.48 (d, J = 10.7 Hz, 1 H), 6.90 (t, J =methyl-1-(1-(tetrahydro-2H- 8.5 Hz, 1 H), 6.13 (s, 1 H), 4.29pyran-4-yl)ethyl)-1H-indole-3- (d, J = 4.5 Hz, 2 H), 4.12 (br. s., 1carboxamide H), 3.94-3.87 (m, 1 H), 3.83 (s, 3 H), 3.64 (dd, J = 3.6,10.9 Hz, 1 H), 3.35 (br. s., 1 H), 3.05 (br. s., 1 H), 2.56 (s, 3 H),2.45-2.37 (m, 1 H), 2.18 (s, 3 H), 1.81 (d, J = 12.7 Hz, 1 H), 1.50 (d,J = 6.9 Hz, 3 H), 1.40- 1.29 (m, 1 H), 1.11-0.99 (m, 1 H), 0.61 (br. s.,1 H) 314 (R or S)-6-chloro-N-((4-methoxy- (400 MHz, DMSO-d₆) δ 11.57 (s,1 472 6-methyl-2-oxo-1,2- H), 7.75 (s, 2 H), 7.66 (d, J = 8.9dihydropyridin-3-yl)methyl)-2- Hz, 1 H), 7.08 (d, J = 8.5 Hz, 1 H),methyl-1-(1-(tetrahydro-2H- 6.14 (s, 1 H), 4.30 (d, J = 4.5 Hz, 2pyran-4-yl)ethyl)-1H-indole-3- H), 4.21-4.05 (m, 2 H), 3.91 (d, J =carboxamide 11.4 Hz, 1 H), 3.85 (s, 3 H), 3.65 (d, J = 10.5 Hz, 1 H),3.02 (t, J = 11.3 Hz, 1 H), 2.58 (s, 3 H), 2.46- 2.31 (m, 1 H), 2.19 (s,3 H), 1.82 (d, J = 12.0 Hz, 1 H), 1.59-1.45 (m, 4 H), 1.44-1.29 (m, 1H), 0.57 (d, J = 12.9 Hz, 1 H) 321 (R or S)-6-methoxy-N-((4- (400 MHz,DMSO-d₆) δ = 11.59 (s, 468 methoxy-6-methyl-2-oxo-1,2- 1 H), 7.67-7.59(m, 2 H), 7.03 (s, dihydropyridin-3-yl)methyl)-2- 1 H), 6.75-6.68 (m, 1H), 6.14 (s, methyl-1-(1-(tetrahydro-2H- 1 H), 4.30 (d, J = 5.1 Hz, 2H), 4.10 pyran-4-yl)ethyl)-1H-indole-3- (dd, J = 7.5, 10.4 Hz, 1 H),3.91 carboxamide (dd, J = 3.0, 11.3 Hz, 1 H), 3.83 (s, 3 H), 3.80-3.76(m, 3 H), 3.68- 3.60 (m, 1 H), 3.38-3.32 (m, 1 H), 3.10-3.00 (m, 1 H),2.56 (s, 3 H), 2.19 (s, 3 H), 1.83 (d, J = 12.7 Hz, 1 H), 1.55-1.43 (m,4 H), 1.34 (br. s., 1 H), 1.10-0.96 (m, 1 H), 0.62 (d, J = 13.4 Hz, 1 H)335 (R or S)-N-((4- 474 (difluoromethoxy)-6-methyl-2-oxo-1,2-dihydropyridin-3- yl)methyl)-2-methyl-1-(1-(tetrahydro-2H-pyran-4-yl)ethyl)- 1H-indole-3-carboxamide 394 (R orS)-N-((4,6-dimethyl-2-oxo- 422 1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(tetrahydro-2H- pyran-4-yl)ethyl)-1H-indole-3- carboxamide442 (R or S)-6-chloro-N-((4,6- 456 dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2- methyl-1-(1-(tetrahydro-2H-pyran-4-yl)ethyl)-1H-indole-3- carboxamide

Step 9: (R orS)—N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(piperidin-4-yl)ethyl)-1H-indole-3-carboxamidehydrochloride (Compound 326)

A 250 mL round bottom flask was charged with a magnetic stir bar, (R orS)-tert-butyl4-(1-(3-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methylcarbamoyl)-2-methyl-1H-indol-1-yl)ethyl)piperidine-1-carboxylate(Compound 327) (1.850 g, 3.45 mmol), MeOH (13.79 ml, 3.45 mmol), and HCl(2.59 ml, 10.34 mmol) (4 N in dioxane). The reaction was allowed to stirat rt for 6 h before being conc. in vacuo to afford the title compound(1.65 g, 3.14 mmol, 91% yield). LCMS 437 (M+1)⁺.

The compound shown in the following table was prepared according to thegeneral procedure outlined in Step 9 using the appropriate startingmaterials. The structure of this compound is shown in FIG. 1.

Compound Number Name ¹H NMR m/z 376 (R or S)-1-(1-(1- (400 MHz, DMSO-d₆)δ 12.27-12.10 (m, 1 476 (azetidin-3-yl)piperidin- H), 11.96-11.72 (m, 1H), 9.80 (br. s., 1 4-yl)ethyl)-N-((4,6- H), 9.19 (br. s., 2 H),7.89-7.67 (m, 2 H), dimethyl-2-oxo-1,2- 7.62 (d, J = 7.6 Hz, 1 H), 7.09(quin, J = 6.6 Hz, dihydropyridin-3- 2 H), 5.99 (s, 1 H), 4.59-4.36 (m,3 H), yl)methyl)-2-methyl-1H- 4.24-3.95 (m, 2 H), 3.48 (d, J = 13.2 Hz,1 indole-3-carboxamide H), 3.17 (d, J = 12.0 Hz, 1 H), 2.87 (br. s., 1hydrochloride H), 2.70 (br. s., 2 H), 2.58 (s, 3 H), 2.34-2.25 (m, 3 H),2.19-2.10 (m, 3 H), 1.75 (d, J = 12.3 Hz, 1 H), 1.57 (d, J = 6.7 Hz, 3H), 1.47 (d, J = 12.7 Hz, 2 H), 1.33-1.21 (m, 2 H), 0.85 (d, J = 13.6Hz, 1 H)

Step 10: (R or S)-isopropyl4-(1-(3-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methylcarbamoyl)-2-methyl-1H-indol-1-yl)ethyl)piperidine-1-carboxylate(Compound 346)

A 250 mL round bottom flask was charged with a magnetic stir bar, (R orS)—N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(piperidin-4-yl)ethyl)-1H-indole-3-carboxamidehydrochloride (0.467 g, 0.987 mmol), DMF (2.468 ml, 0.987 mmol), THF(2.468 ml, 0.987 mmol), and N-ethyl-N-isopropylpropan-2-amine (0.638 g,4.94 mmol). The reaction was cooled to 0° C. and isopropylcarbonochloridate (0.160 ml, 1.086 mmol) was added drop wise viasyringe. The reaction was allowed to stir for 2 h to rt and was thentreated with 5 N LiOH for 1 h to remove any acylated pyridone. Thismaterial was extracted with ethyl acetate, washed with brine, dried withMgSO₄ and filtered and conc. in vacuo. The resulting material waspurified via silica gel chromatography (50 g) using ethyl acetate/MeOH(5:1) as eluent to afford pure title compound as a pale yellow solid(0.300 g, 0.545 mmol, 55.2% yield). LCMS 523 (M+1)⁺; ¹H NMR (DMSO-d6,400 MHz) δ 11.59 (br. s., 1H), 7.74 (d, J=7.8 Hz, 1H), 7.69 (t, J=4.9Hz, 1H), 7.62 (d, J=7.8 Hz, 1H), 7.13-7.01 (m, 2H), 6.15 (s, 1H),4.78-4.67 (m, 1H), 4.32 (d, J=4.9 Hz, 2H), 4.23-4.12 (m, 1H), 4.12-4.02(m, 1H), 3.84 (s, 3H), 3.82-3.74 (m, 1H), 2.79-2.66 (m, 1H), 2.58 (s,3H), 2.46-2.34 (m, 2H), 2.20 (s, 3H), 1.96-1.88 (m, 1H), 1.58-1.46 (m,4H), 1.15 (d, J=6.0 Hz, 6H), 0.95-0.89 (m, 1H), 0.74-0.65 (m, 1H).

The compounds shown in the following table were prepared according tothe general procedure outlined in Step 10 using the appropriate startingmaterials. The structures of the compounds are shown in FIG. 1.

Compound Number Name ¹H NMR m/z 336 (R or S)-N-((4-methoxy-6-methyl-2-(400 MHz, DMSO-d₆) δ = 11.59 (s, 515 oxo-1,2-dihydropyridin-3- 1 H),7.78-7.66 (m, 2 H), yl)methyl)-2-methyl-1-(1-(1- 7.64-7.57 (m, 1 H),7.06 (s, 2 (methylsulfonyl)piperidin-4- H), 6.14 (s, 1 H), 4.31 (d, J =4.9 Hz, yl)ethyl)-1H-indole-3-carboxamide 2 H), 4.25-4.15 (m, 1 H), 3.83(s, 3 H), 3.63 (s, 1 H), 3.40-3.33 (m, 1 H), 2.79 (s, 3 H), 2.75-2.65(m, 1 H), 2.60 (s, 3 H), 2.45-2.27 (m, 1 H), 2.19 (s, 3 H), 2.06-1.98(m, 1 H), 1.55 (d, J = 6.9 Hz, 3 H), 1.45-1.36 (m, 1 H), 1.28-1.18 (m, 1H), 1.14-1.03 (m, 1 H), 0.83-0.74 (m, 1 H) 337 (R orS)-1-(1-(1-(2-hydroxy-2- (400 MHz, DMSO-d₆) δ 523methylpropanoyl)piperidin-4- 11.58 (br. s., 1 H), 7.77-7.67 (m, 2yl)ethyl)-N-((4-methoxy-6-methyl-2- H), 7.66-7.60 (m, 1 H), 7.06 (s,oxo-1,2-dihydropyridin-3- 2 H), 6.14 (s, 1 H),yl)methyl)-2-methyl-1H-indole-3- 5.32-5.23 (m, 1 H), 4.31 (d, J = 4.5Hz, 2 carboxamide H), 4.19-4.10 (m, 1 H), 3.83 (s, 3 H), 2.75-2.62 (m, 2H), 2.58 (s, 3 H), 2.19 (s, 4 H), 2.00-1.90 (m, 2 H), 1.54 (d, J = 6.7Hz, 3 H), 1.32-1.18 (m, 8 H), 0.87-0.78 (m, 1 H), 0.77-0.67 (m, 1 H) 342(R or S)-1-(1-(1-isobutyrylpiperidin- (400 MHz, DMSO-d₆) δ = 11.59 (s,507 4-yl)ethyl)-N-((4-methoxy-6-methyl- 1 H), 7.75 (d, J = 7.4 Hz, 12-oxo-1,2-dihydropyridin-3- H), 7.72-7.67 (m, 1 H),yl)methyl)-2-methyl-1H-indole-3- 7.64 (d, J = 8.0 Hz, 1 H), carboxamide7.14-7.01 (m, 2 H), 6.15 (s, 1 H), 4.58-4.46 (m, 1 H), 4.32 (d, J = 4.9Hz, 2 H), 4.09-3.99 (m, 1 H), 3.84 (s, 3 H), 3.81-3.72 (m, 1 H),3.08-2.97 (m, 1 H), 2.92-2.81 (m, 1 H), 2.78-2.65 (m, 3 H), 2.59 (br.s., 3 H), 2.20 (s, 3 H), 2.03-1.90 (m, 1 H), 1.59-1.47 (m, 4 H),1.02-0.86 (m, 6 H), 0.78-0.69 (m, 1 H) 344 (R orS)-N-((4-(difluoromethoxy)-6- (400 MHz, DMSO-d₆) δ 551methyl-2-oxo-1,2-dihydropyridin-3- 12.02-11.95 (m, 1 H), 7.74 (d, J =8.0 Hz, yl)methyl)-2-methyl-1-(1-(1- 1 H), 7.66-7.57 (m, 2 H),(methylsulfonyl)piperidin-4- 7.11-7.00 (m, 2 H), 6.08 (s, 1yl)ethyl)-1H-indole-3-carboxamide H), 4.32 (d, J = 4.5 Hz, 2 H), 4.18(d, J = 7.1 Hz, 1 H), 3.64 (d, J = 12.3 Hz, 1 H), 3.36 (d, J = 12.0 Hz,1 H), 2.79 (s, 3 H), 2.75-2.65 (m, 2 H), 2.58 (s, 3 H), 2.45-2.27 (m, 2H), 2.20 (s, 3 H), 2.07-1.98 (m, 1 H), 1.55 (d, J = 6.9 Hz, 3 H), 1.40(d, J = 8.2 Hz, 1 H), 1.10 (d, J = 8.9 Hz, 1 H), 0.79 (d, J = 12.5 Hz, 1H) 345 (R or S)-1-(1-(1- (400 MHz, DMSO-d₆) δ 529(ethylsulfonyl)piperidin-4-yl)ethyl)- 11.57 (s, 1 H), 7.75 (d, J = 8.0Hz, 1 N-((4-methoxy-6-methyl-2-oxo-1,2- H), 7.69 (t, J = 5.0 Hz, 1 H),dihydropyridin-3-yl)methyl)-2- 7.62 (d, J = 7.4 Hz, 1 H),methyl-1H-indole-3-carboxamide 7.06 (d, J = 7.1 Hz, 2 H), 6.15 (s, 1 H),4.32 (d, J = 5.1 Hz, 2 H), 4.25-4.15 (m, 1 H), 3.84 (s, 3 H), 3.73-3.65(m, 1 H), 3.45-3.36 (m, 1 H), 3.02-2.93 (m, J = 7.8 Hz, 2 H), 2.87-2.77(m, 1 H), 2.75-2.66 (m, 1 H), 2.60 (s, 3 H), 2.42-2.30 (m, 1 H), 2.20(s, 3 H), 2.06-1.97 (m, 1 H), 1.58-1.48 (m, 4 H), 1.42-1.31 (m, 1 H),1.17 (t, J = 7.5 Hz, 3 H), 1.13-1.00 (m, 1 H), 0.83-0.73 (m, 1 H) 355 (Ror S)-1-(1-(4- (400 MHz, DMSO-d₆) δ 543(isopropylsulfonyl)cyclohexyl)ethyl)- 11.59 (s, 1H), 7.76-7.69 (m, 2H),N-((4-methoxy-6-methyl-2-oxo-1,2- 7.62 (d, 1H), 7.10-7.03 (m, 2H),dihydropyridin-3-yl)methyl)-2- 6.15 (s, 1H), 4.32 (d, 2H),methyl-1H-indole-3-carboxamide 4.29-4.26 (m, 2H), 3.84 (s, 3H), 3.72(br. d., 1H), 3.45 (br. d., 1H), 3.26 (tt, 1H), 2.91 (dt, 1H), 2.60 (s,3H), 2.20 (s, 3H), 1.97 (br. d., 1H), 1.54 (d, 3H), 1.35-1.24 (m, 2H),1.18 (d, 3H), 1.16 (d, 3H), 1.05-0.78 (m, 2H) 357 (R or S)-isobutyl4-(1-(3-(((4- (400 MHz, DMSO-d₆) δ 537 methoxy-6-methyl-2-oxo-1,2- 11.60(br.s., 1H), 7.75-7.60 (m, dihydropyridin-3- 3H), 7.10-7.03 (m, 2H),6.15 (s, yl)methyl)carbamoyl)-2-methyl-1H- 1H) 4.33 (d, 1H), 4.13-4.06(m, indol-1-yl)ethyl)piperidine-1- 1H), 3.84 (s, 3H), 3.74 (d, 1H),carboxylate 2.80-2.60 (m, 3H), 2.58 (s, 1H), 2.50-2.42 (m, 2H),1.96-1.90 (m, 1H), 1.54 (d, 3H), 1.25-1.22 (m, 1H), 0.98-0.72 (m, 6H)368 (R or S)-N-((4,6-dimethyl-2-oxo-1,2- (400 MHz, DMSO-d₆) δ 513dihydropyridin-3-yl)methyl)-1-(1-(1- 11.59 (s, 1 H), 7.78-7.71 (m, 1 H),(ethylsulfonyl)piperidin-4-yl)ethyl)- 7.66-7.57 (m, 2 H), 7.07 (s, 22-methyl-1H-indole-3-carboxamide H), 5.89 (s, 1 H), 4.32 (s, 2 H),4.25-4.15 (m, 1 H), 3.65-3.59 (m, 1 H), 3.19-3.10 (m, 1 H), 2.98 (d, J =7.4 Hz, 2 H), 2.87-2.77 (m, 1 H), 2.72-2.65 (m, 1 H), 2.58 (s, 3 H),2.27 (s, 3 H), 2.12 (s, 3 H), 1.55 (d, J = 6.9 Hz, 4 H), 1.42-1.33 (m, 2H), 1.17 (t, J = 7.4 Hz, 3 H), 1.12-1.00 (m, 1 H), 0.84-0.74 (m, 1 H)382 (R or S)-N-((4,6-dimethyl-2-oxo-1,2- (400 MHz, DMSO-d₆) δ 499dihydropyridin-3-yl)methyl)-2- 11.60 (s, 1 H), 7.75 (d, J = 7.1 Hz, 1methyl-1-(1-(1- H), 7.65-7.58 (m, 2 H), (methylsulfonyl)piperidin-4-7.12-7.02 (m, 2 H), 5.89 (s, 1 H), yl)ethyl)-1H-indole-3-carboxamide4.38-4.25 (m, 2 H), 4.20 (dd, J = 7.0, 10.6 Hz, 1 H), 2.80 (s, 3 H),2.76-2.67 (m, 2 H), 2.59 (s, 3 H), 2.46-2.31 (m, 2 H), 2.27 (s, 3 H),2.12 (s, 3 H), 1.55 (d, J = 6.9 Hz, 3 H), 1.51 (br. s., 1 H), 1.47-1.34(m, 1 H), 1.29-1.21 (m, 1 H), 1.17-1.04 (m, 1 H), 0.80 (d, J = 12.9 Hz,1 H)

Example 2 Synthesis of (R orS)-1-(1-(1-isopropylpiperidin-4-yl)ethyl)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1H-indole-3-carboxamide(Compound 358)

A 25 mL vial was charged with a magnetic stir bar, (R orS)—N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(piperidin-4-yl)ethyl)-1H-indole-3-carboxamidehydrochloride, THF (2.114 ml, 0.211 mmol), propan-2-one (0.061 g, 1.057mmol), and sodium triacetoxyborohydride (0.224 g, 1.057 mmol). Thereaction was allowed to stir at rt for 12 h. The reaction was inversequenched onto sat'd aqueous NaHCO₃, extracted with ethyl acetate andconc. in vacuo. The resulting material was treated with 10 mL 7 Nammonia in MeOH and was conc in vacuo to yield material which waspurified via silica gel chromatography (10 g) using DCM/MeOH/NH₄OH(90:1:0.1) as eluent to afford 33 mg, (0.065 mmol, 31.0% yield) of thetitle compound as a white solid.). LCMS 479 (M+1)⁺; ¹H NMR (DMSO-d6, 400MHz)

δ 11.59 (s., 1H), 7.64-7.82 (m, 2H), 7.59 (d, 1H), 6.95-7.17 (m, 2H),6.15 (s, 1H), 4.32 (d, 2H), 4.04-4.24 (m, 1H), 3.84 (□, 3H), 2.77-2.93(□, 2H), 2.68 (□, 1H), 2.60 (□, 3H), 2.20 (□, 3H), 2.08-2.15 (□, 1H),1.92 (□, 1H), 1.83 (□p. □., 1H), 1.54 (□, 3H), 1.27-1.43 (□, 2H), 0.91(□, 6H), 0.71-0.67 (□, 2H).

The compounds shown in the following table were prepared according tothe general procedure outlined in this Example using the appropriatestarting materials. The structures of the compounds are shown in FIG. 1.

Compound Number Name ¹H NMR m/z 341 (R or S)-N-((4-methoxy- (400 MHz,DMSO-d₆) δ 11.58 (s, 1 H), 493 6-methyl-2-oxo-1,2- 7.76-7.65 (m, 2 H),7.59 (d, J = 7.8 Hz, 1 dihydropyridin-3- H), 7.10-6.99 (m, 2 H), 6.14(s, 1 H), yl)methyl)-2-methyl-1- 4.49 (t, J = 6.4 Hz, 1 H), 4.43 (t, J =6.5 Hz, 1 (1-(1-(oxetan-3- H), 4.37 (t, J = 6.1 Hz, 1 H), 4.34-4.28 (m,yl)piperidin-4-yl)ethyl)- 3 H), 4.21-4.10 (m, 1 H), 3.83 (s, 3 H),1H-indole-3- 3.30-3.23 (m, 1 H), 2.75 (br. s., 1 H), carboxamide2.71-2.64 (m, 1 H), 2.60 (s, 3 H), 2.19 (s, 4 H), 1.90 (br. s., 1 H),1.75 (br. s., 1 H), 1.53 (d, J = 6.9 Hz, 3 H), 1.42 (br. s., 2 H),1.11-0.98 (m, 1 H), 0.72-0.63 (m, 1 H) 343 (R or S)-N-((4-methoxy- (400MHz, DMSO-d₆) δ 11.58 (s, 1 H), 451 6-methyl-2-oxo-1,2- 7.76-7.65 (m, 2H), 7.59 (d, J = 7.6 Hz, 1 dihydropyridin-3- H), 7.11-6.99 (m, 2 H),6.14 (s, 1 H), yl)methyl)-2-methyl-1- 4.31 (d, J = 5.1 Hz, 2 H), 4.13(br. s., 1 H), (1-(1-methylpiperidin-4- 3.83 (s, 3 H), 2.83 (d, J = 10.0Hz, 1 H), yl)ethyl)-1H-indole-3- 2.61-2.52 (m, 5 H), 2.19 (s, 3 H), 2.09(s, 4 H), carboxamide 1.88 (d, J = 10.7 Hz, 2 H), 1.53 (d, J = 6.7 Hz, 3H), 1.34 (br. s., 1 H), 1.02 (d, J = 8.2 Hz, 1 H), 0.66 (br. s., 1 H)359 (R or S)-N-((4-methoxy- (400 MHz, DMSO-d₆) δ 11.59 (s, 1 H), 4956-methyl-2-oxo-1,2- 7.77-7.66 (m, 2 H), 7.60 (d, J = 7.8 Hz, 1dihydropyridin-3- H), 7.12-7.01 (m, 2 H), 6.15 (s, 1 H),yl)methyl)-1-(1-(1-(2- 4.32 (d, J = 4.9 Hz, 2 H), 4.13 (d, J = 7.1 Hz, 1methoxyethyl)piperidin- H), 3.85 (s, 3 H), 3.36 (t, J = 5.9 Hz, 2 H),4-yl)ethyl)-2-methyl-1H- 3.19 (s, 3 H), 2.94 (d, J = 10.5 Hz, 1 H),indole-3-carboxamide 2.71-2.56 (m, 5 H), 2.43-2.32 (m, 2 H), 2.24-2.12(m, 4 H), 1.54 (d, J = 6.9 Hz, 4 H), 1.39-1.27 (m, 2 H), 1.02 (d, J =8.7 Hz, 1 H), 0.65 (d, J = 12.7 Hz, 1 H) 360 (R or S)-1-(1-(1- (400 MHz,DMSO-d₆) δ 11.79-11.45 (m, 1 465 ethylpiperidin-4- H), 7.78-7.65 (m, 2H), 7.59 (d, J = 7.8 Hz, yl)ethyl)-N-((4- 1 H), 7.14-6.99 (m, 2 H), 6.15(s, 1 H), methoxy-6-methyl-2- 4.32 (d, J = 4.9 Hz, 2 H), 4.20-4.08 (m, 1oxo-1,2-dihydropyridin- H), 3.84 (s, 3 H), 2.98-2.89 (m, 1 H),3-yl)methyl)-2-methyl- 2.71-2.61 (m, 2 H), 2.59 (s, 3 H), 1H-indole-3-2.27-2.21 (m, 2 H), 2.20 (s, 3 H), 1.94-1.80 (m, 2 H), carboxamide 1.54(s, 4 H), 1.38-1.28 (m, 1 H), 1.06-0.98 (m, 1 H), 0.93 (t, J = 7.1 Hz, 3H), 0.71-0.63 (m, 1 H) 363 (R or S)-ethyl 2-(4-(1-(3- (400 MHz, DMSO-d₆)δ 11.59 (br. s., 1 H), 523 (((4-methoxy-6-methyl- 7.81-7.65 (m, 2 H),7.60 (d, J = 7.4 Hz, 1 2-oxo-1,2- H), 7.16-6.98 (m, 2 H), 6.15 (s, 1 H),dihydropyridin-3- 4.32 (d, J = 4.9 Hz, 2 H), 4.23-4.11 (m, 1 H),yl)methyl)carbamoyl)-2- 4.04 (q, J = 7.0 Hz, 2 H), 3.84 (s, 3 H),methyl-1H-indol-1- 2.95-2.86 (m, 1 H), 2.60 (s, 5 H), 2.20 (s, 4 H),yl)ethyl)piperidin-1- 1.94-1.79 (m, 2 H), 1.54 (d, J = 6.9 Hz, 4yl)acetate H), 1.41-1.32 (m, 1 H), 1.15 (t, J = 7.1 Hz, 3 H), 1.04 (d, J= 6.0 Hz, 2 H), 0.71-0.61 (m, 1 H) 366 (R or S)-N-((4-ethyl-6- (400 MHz,DMSO-d₆) δ 11.63 (s, 1 H), 449 methyl-2-oxo-1,2- 7.74 (d, J = 7.6 Hz, 1H), 7.65-7.56 (m, 2 dihydropyridin-3- H), 7.12-7.01 (m, 2 H), 5.94 (s, 1H), yl)methyl)-2-methyl-1- 4.34 (t, J = 5.1 Hz, 2 H), 4.19-4.09 (m, 1H), (1-(1-methylpiperidin-4- 2.88 (br. s., 1 H), 2.71-2.56 (m, 6 H),yl)ethyl)-1H-indole-3- 2.14 (s, 7 H), 1.91 (d, J = 12.5 Hz, 1 H), 1.54(d, carboxamide J = 6.9 Hz, 4 H), 1.41-1.31 (m, 2 H), 1.14 (t, J = 7.6Hz, 3 H), 1.05 (d, J = 9.1 Hz, 1 H), 0.68 (d, J = 12.7 Hz, 1 H) 367 (Ror S)-N-((4,6- (400 MHz, DMSO-d₆) δ 11.59 (s, 1 H), 435dimethyl-2-oxo-1,2- 7.74 (d, J = 6.9 Hz, 1 H), 7.65-7.56 (m, 2dihydropyridin-3- H), 7.12-7.01 (m, 2 H), 5.89 (s, 1 H),yl)methyl)-2-methyl-1- 4.38-4.25 (m, 2 H), 4.20-4.09 (m, 1 H),(1-(1-methylpiperidin-4- 2.95 (br. s., 1 H), 2.68 (br. s., 2 H), 2.58(s, 3 H), yl)ethyl)-1H-indole-3- 2.27 (s, 3 H), 2.21 (br. s., 3 H), 2.12(s, 3 carboxamide H), 1.94 (d, J = 13.8 Hz, 1 H), 1.54 (d, J = 6.9 Hz, 4H), 1.44-1.31 (m, 2 H), 1.07 (d, J = 12.5 Hz, 1 H), 0.71 (d, J = 13.2Hz, 1 H) 375 (R or S)-N-((4,6- (400 MHz, DMSO-d₆) δ 11.59 (br. s., 1 H),477 dimethyl-2-oxo-1,2- 7.73 (d, J = 7.6 Hz, 1 H), 7.65-7.55 (m, 2dihydropyridin-3- H), 7.12-7.00 (m, 2 H), 5.89 (s, 1 H),yl)methyl)-2-methyl-1- 4.53-4.48 (m, 1 H), 4.47-4.42 (m, 1 H),(1-(1-(oxetan-3- 4.38 (s, 1 H), 4.31 (t, J = 5.2 Hz, 3 H),yl)piperidin-4-yl)ethyl)- 4.21-4.10 (m, 1 H), 3.31-3.24 (m, 2 H),1H-indole-3- 2.81-2.64 (m, 2 H), 2.59 (s, 3 H), 2.26 (s, 3 H),carboxamide 2.23-2.16 (m, 1 H), 2.12 (s, 3 H), 1.98-1.85 (m, 1 H),1.81-1.70 (m, 1 H), 1.54 (d, J = 6.9 Hz, 3 H), 1.51-1.22 (m, 1 H),1.12-0.96 (m, 2 H), 0.73-0.64 (m, 1 H) 380 (R or S)-N-((4-ethyl-6- (400MHz, DMSO-d₆) δ 11.63 (br. s., 1 H), 491 methyl-2-oxo-1,2- 7.74 (d, J =7.36 Hz, 1 H), 7.60 (d, J = 8.47 Hz, dihydropyridin-3- 2 H), 7.06 (quin,J = 7.13 Hz, 3 H), yl)methyl)-2-methyl-1- 5.94 (s, 1 H), 4.51 (t, J =6.47 Hz, 1 H), (1-(1-(oxetan-3- 4.46 (t, J = 6.35 Hz, 1 H), 4.40 (t, J =6.13 Hz, yl)piperidin-4-yl)ethyl)- 1 H), 4.37-4.30 (m, 2 H),1H-indole-3- 4.28-4.11 (m, 1 H), 3.57 (s, 1 H), 3.34 (br. s., 2 H),carboxamide 2.81 (d, J = 10.70 Hz, 1 H), 2.67 (d, J = 14.94 Hz, 1 H),2.64-2.57 (m, 4 H), 2.21 (d, J = 10.93 Hz, 1 H), 2.14 (s, 3 H), 1.93 (d,J = 12.49 Hz, 1 H), 1.83 (t, J = 11.37 Hz, 1 H), 1.54 (d, J = 6.91 Hz, 3H), 1.37 (d, J = 10.48 Hz, 1 H), 1.25 (q, J = 6.91 Hz, 1 H), 1.14 (t, J= 7.58 Hz, 3 H), 1.06 (d, J = 9.81 Hz, 1 H), 0.70 (d, J = 12.49 Hz, 1 H)381 (R or S)-N-((4,6- ¹H NMR (400 MHz, DMSO-d₆) δ 505dimethyl-2-oxo-1,2- 11.60 (br. s., 1 H), 7.74 (d, J = 7.13 Hz, 1 H),dihydropyridin-3- 7.66-7.50 (m, 2 H), 7.15-6.99 (m, 2 H),yl)methyl)-2-methyl-1- 5.89 (s, 1 H), 4.40-4.24 (m, 2 H),(1-(1-(tetrahydro-2H- 4.21-4.07 (m, 1 H), 3.95-3.78 (m, 2 H), 3.57 (s, 1H), pyran-4-yl)piperidin-4- 3.32-3.17 (m, 3 H), 2.68 (br. s., 1 H),yl)ethyl)-1H-indole-3- 2.58 (s, 3 H), 2.33 (br. s., 2 H), 2.27 (s, 3 H),carboxamide 2.12 (s, 3 H), 2.00-1.88 (m, 2 H), 1.75 (d, J = 12.04 Hz, 1H), 1.62 (br. s., 2 H), 1.54 (d, J = 6.91 Hz, 3 H), 1.46-1.30 (m, 2 H),1.01 (br. s., 1 H), 0.72 (br. s., 1 H) 440 (R or S)-tert-butyl 3-(4- 576(1-(3-(((4,6-dimethyl-2- oxo-1,2-dihydropyridin- 3-yl)methyl)carbamoyl)-2-methyl-1H-indol-1- yl)ethyl)piperidin-1- yl)azetidine-1- carboxylate377 (R or S)-N-((4,6- (400 MHz, DMSO-d₆) δ 11.63-11.56 (m, 1 490dimethyl-2-oxo-1,2- H), 7.76-7.70 (m, 1 H), 7.64-7.55 (m, 2dihydropyridin-3- H), 7.05 (s, 2 H), 5.89 (s, 1 H), 4.56 (s, 4yl)methyl)-2-methyl-1- H), 4.31 (s, 2 H), 4.19-4.09 (m, 1 H),(1-(1-(1-methylazetidin- 3.36 (d, J = 4.9 Hz, 1 H), 2.77-2.56 (m, 5 H),3-yl)piperidin-4- 2.26 (s, 3 H), 2.18 (s, 3 H), 2.12 (s, 3 H),yl)ethyl)-1H-indole-3- 1.94-1.85 (m, 1 H), 1.78-1.67 (m, 1 H),carboxamide 1.53 (d, J = 6.9 Hz, 3 H), 1.50-1.45 (m, 1 H), 1.44-1.22 (m,2 H), 1.07-0.93 (m, 1 H), 0.71-0.61 (m, 1 H)

Example 3 Synthesis of (R orS)-1-(1-(1-(2-fluoroethyl)piperidin-4-yl)ethyl)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1H-indole-3-carboxamide(Compound 356)

A 25 mL vial was charged with a magnetic stir bar, (R orS)—N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(piperidin-4-yl)ethyl)-1H-indole-3-carboxamidehydrochloride (0.062 g, 0.131 mmol), K₂CO₃ (0.072 g, 0.524 mmol), MeCN(0.655 ml, 0.131 mmol), DMF (0.262 ml, 0.131 mmol) and1-bromo-2-fluoroethane (0.020 ml, 0.262 mmol). The reaction was cappedand heated to 82° C. with stirring for 4 h. The reaction was allowed tocool to rt, filtered, and the filtrate was pre-absorbed onto silica gel(12 g). The material was purified via SiO₂ chromatography (25 g) usingDCM/MeOH/Et₃N (85:15:0.5) as eluent to afford the title compound as anoff white solid (30 mg, 0.059 mmol, 45.1% yield). LCMS 483 (M+1)⁺; ¹HNMR (DMSO-d6, 400 MHz) δ 11.59 (s, 1H), 7.75-7.68 (m, 2H), 7.60 (d, 1H)7.09-7.03 (m, 2H), 6.15 (s, 1H) 4.53-4.51 (m, 1H), 4.42-4.39 (m, 1H),4.32 (d, 2H), 4.24-4.2 (m, 1H), 3.84 (s, 3H), 2.98 (br. d., 1H),2.70-2.49 (m, 4H), 2.60 (s, 3H), 2.20 (s, 3H), 2.01 (dt, 1H), 1.92-1.90(m, 1H), 1.75-1.71 (m, 1H), 1.54 (d, 3H), 1.38-1.36 (m, 1H), 1.02-0.98(m, 1H), 0.7-0.66 (br. d., 1H).

The compounds shown in the following table were prepared according tothe general procedure outlined in this Example using the appropriatestarting materials. The structures of the compounds are shown in FIG. 1.

Compound Number Name ¹H NMR m/z 362 (R or S)-1-(1-(1-(2,2- (400 MHz,DMSO-d₆) δ J = 11.60 (br. s., 1 501 difluoroethyl)piperidin- H),7.77-7.66 (m, 2 H), 7.60 (d, J = 7.6 Hz, 4-yl)ethyl)-N-((4- 1 H),7.14-7.00 (m, 2 H), 6.15 (s, 1 H), methoxy-6-methyl-2- 6.06 (t, J = 55.7Hz, 1 H), 4.32 (d, J = 4.9 Hz, oxo-1,2-dihydropyridin- 2 H), 4.15 (br.s., 1 H), 3.84 (s, 3 H), 3-yl)methyl)-2-methyl- 3.03-2.93 (m, 2 H),2.73-2.62 (m, 3 H), 1H-indole-3- 2.60 (s, 3 H), 2.26-2.10 (m, 4 H),carboxamide 1.93-1.79 (m, 1 H), 1.59-1.46 (m, 4 H), 1.41-1.29 (m, 1 H),1.11-0.97 (m, 1 H), 0.67 (br. s., 1 H) 378 (R or S)-N-((4-methoxy- (400MHz, DMSO-d₆) δ J = 11.60 (br. s., 1 H), 533 6-methyl-2-oxo-1,2-7.78-7.66 (m, 2 H), 7.60 (d, J = 8.2 Hz, 1 dihydropyridin-3- H),7.13-7.00 (m, 2 H), 6.15 (s, 1 H), yl)methyl)-2-methyl-1- 4.32 (d, J =4.9 Hz, 2 H), 4.22-4.09 (m, 1 H), (1-(1-(3,3,3- 3.84 (s, 3 H), 3.03-2.91(m, 1 H), trifluoropropyl)piperidin- 2.73-2.64 (m, 1 H), 2.60 (s, 3 H),2.48-2.31 (m, 4-yl)ethyl)-1H-indole-3- 5 H), 2.20 (s, 3 H), 2.01-1.85(m, 2 H), carboxamide 1.58-1.46 (m, 4 H), 1.36-1.29 (m, 1 H), 1.08-0.98(m, 1 H), 0.73-0.62 (m, 1 H) 365 (R or S)-N-((4-methoxy- (500 MHz,DMSO-d₆) δ J = 11.59 (s, 1 H), 519 6-methyl-2-oxo-1,2- 7.74 (d, J = 7.6Hz, 1 H), 7.71-7.66 (m, 1 dihydropyridin-3- H), 7.61 (d, J = 7.8 Hz, 1H), 7.13-7.01 (m, yl)methyl)-2-methyl-1- 2 H), 6.15 (s, 1 H), 4.32 (d, J= 4.9 Hz, 2 H), (1-(1-(2,2,2- 4.22-4.12 (m, 1 H), 3.84 (s, 3 H),trifluoroethyl)piperidin- 3.15-2.95 (m, 3 H), 2.75-2.66 (m, 1 H), 2.60(s, 4-yl)ethyl)-1H-indole-3- 3 H), 2.39-2.31 (m, 1 H), 2.20 (s, 3 H),carboxamide 2.05-1.98 (m, 1 H), 1.92-1.84 (m, 1 H), 1.56-1.46 (m, 4 H),1.42-1.32 (m, 1 H), 1.11-1.01 (m, 1 H), 0.69-0.62 (m, 1 H) 441 (R orS)-1-(1-(1-(2,2- (400 MHz, DMSO-d₆) δ = 11.59 (s, 1 H), 485difluoroethyl)piperidin- 7.73 (d, J = 7.8 Hz, 1 H), 7.65-7.55 (m, 24-yl)ethyl)-N-((4,6- H), 7.12-7.00 (m, 2 H), 6.22-5.90 (m, 1dimethyl-2-oxo-1,2- H), 5.89 (s, 1 H), 4.36-4.25 (m, 2 H),dihydropyridin-3- 4.20-4.09 (m, 1 H), 3.01-2.93 (m, 1 H),yl)methyl)-2-methyl-1H- 2.72-2.59 (m, 3 H), 2.58 (s, 3 H), 2.26 (s, 3H), indole-3-carboxamide 2.21-2.13 (m, 2 H), 2.12 (s, 3 H), 1.92-1.79(m, 2 H), 1.53 (s, 4 H), 1.41-1.29 (m, 1 H), 1.10-0.97 (m, 1 H),0.70-0.59 (m, 1 H)

Example 4 Synthesis of (R orS)—N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(pyrimidin-2-yl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide(Compound 361)

To a re-sealable vial was added 2-chloropyrimidine (185 mg, 1.611 mmol),(R orS)—N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(piperidin-4-yl)ethyl)-1H-indole-3-carboxamidehydrochloride (508 mg, 1.074 mmol), and EtOH (8 mL). To this solutionwas added Et₃N (449 μl, 3.22 mmol). The vial was sealed and heated to100° C. overnight. The solution was allowed to cool to room temperatureand concentrated in vacuo. The crude residue was purified via silica gelchromatography (hexanes: (3:2 DCM:IPA)) to afford the title compound asa solid (357 mg, 0.694 mmol, 64.6% yield). LCMS 515 (M+1)⁺; ¹H NMR(DMSO-d6, 400 MHz) δ 11.60 (s, 1H), 8.30 (d, J=4.7 Hz, 2H), 7.76 (d,J=7.6 Hz, 1H), 7.73-7.64 (m, 2H), 7.14-7.01 (m, 2H), 6.55 (t, J=4.7 Hz,1H), 6.15 (s, 1H), 4.84-4.75 (m, 1H), 4.57-4.47 (m, 1H), 4.33 (d, J=4.2Hz, 2H), 4.22-4.11 (m, 1H), 3.84 (s, 3H), 2.92-2.81 (m, 1H), 2.63-2.52(m, 4H), 2.20 (s, 3H), 2.05-1.94 (m, 1H), 1.61-1.49 (m, 4H), 1.34-1.21(m, 1H), 1.04-0.91 (m, 1H), 0.83-0.75 (m, 1H).

The compound shown in the following table was prepared according to thegeneral procedure outlined in this Example using the appropriatestarting materials. The structure of the compound is shown in FIG. 1.

Compound Number Name ¹H NMR m/z 373 (R or S)-N-((4- (400 MHz, DMSO-d₆) δ11.60 (br. s., 1 H), 514 methoxy-6-methyl- 8.06 (d, J = 3.6 Hz, 1 H),7.82-7.62 (m, 3 H), 2-oxo-1,2- 7.51-7.39 (m, 1 H), 7.17-6.98 (m, 2 H),6.75 (d, J = 8.5 Hz, dihydropyridin-3- 1 H), 6.61-6.49 (m, 1 H), 6.15(s, 1 H), yl)methyl)-2- 4.49-4.38 (m, 1 H), 4.33 (d, J = 3.8 Hz, 2 H),methyl-1-(1-(1- 4.24-4.03 (m, 2 H), 3.85 (s, 3 H), (pyridin-2- 2.90-2.70(m, 2 H), 2.58 (s, 3 H), 2.20 (s, 3 H), yl)piperidin-4- 2.06-1.91 (m, 1H), 1.63-1.47 (m, 4 H), 1.40-1.27 (m, 1 yl)ethyl)-1H- H), 1.07-0.94 (m,1 H), 0.82-0.72 (m, 1 H) indole-3- carboxamide

Example 5 Synthesis of (R orS)-1-(1-(1-(2-hydroxyethyl)piperidin-4-yl)ethyl)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1H-indole-3-carboxamide(Compound 347)

To a sealed tube charged with a magnetic stir bar was added (R orS)—N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(piperidin-4-yl)ethyl)-1H-indole-3-carboxamide(0.1 g, 0.229 mmol) was added DCM (3 mL) and the reaction cooled to 0°C. To the cooled reaction mixture was added oxirane which was condensedinto the reaction vial (˜1 mL). The reaction was allowed to stir to rtover 4 h and was then conc. in vacuo to afford the crude material whichwas purified via silica gel chromatography (12 g) using ethylacetate/MeOH (4:1) as eluent to afford the title compound as a whitesolid (50 mg). LCMS 481 (M+1)⁺; ¹H NMR (DMSO-d6, 400 MHz) δ) δ 11.58 (s,1H), 7.77-7.65 (m, 2H), 7.59 (d, J=7.8 Hz, 1H), 7.11-6.99 (m, 2H), 6.14(s, 1H), 4.54-4.44 (m, 1H), 4.31 (d, J=5.1 Hz, 3H), 4.13 (dd, J=7.1,10.3 Hz, 1H), 3.83 (s, 3H), 3.42 (q, J=6.0 Hz, 2H), 2.93 (br. s., 1H),2.71-2.56 (m, 4H), 2.31 (br. s., 2H), 2.19 (s, 3H), 2.03-1.83 (m, 2H),1.64 (br. s., 1H), 1.53 (d, J=6.9 Hz, 3H), 1.32 (d, J=11.1 Hz, 1H), 1.02(d, J=10.3 Hz, 1H), 0.65 (d, J=11.8 Hz, 1H).

The compounds shown in the following table were prepared according tothe general procedure outlined in this Example using the appropriatestarting materials. The structures of the compounds are shown in FIG. 1.

Compound Number Name ¹H NMR m/z 352 (R or S)-1-(1-(1-(2- NMR (400 MHz,DMSO-d6) δ 11.58 (br. s., 1 509 hydroxy-2- H), 7.76-7.65 (m, 2 H), 7.58(d, J = 7.8 Hz, 1 methylpropyl)piperidin- H), 7.10-6.99 (m, 2 H), 6.14(s, 1 H), 4.31 (d, 4-yl)ethyl)-N-((4- J = 4.9 Hz, 2 H), 4.14 (br. s., 1H), 3.94 (s, 1 methoxy-6-methyl-2- H), 3.83 (s, 3 H), 3.56 (s, 2 H),3.01 (d, J = 11.4 Hz, oxo-1,2- 1 H), 2.73-2.64 (m, 1 H), 2.59 (s, 3dihydropyridin-3- H), 2.19 (s, 3 H), 2.16-2.03 (m, 2 H), 1.52 (d,yl)methyl)-2-methyl- J = 6.9 Hz, 4 H), 1.34 (br. s., 2 H), 1.02 (d, J =4.5 Hz, 1H-indole-3- 7 H), 0.66-0.58 (m, 1 H) carboxamide 369 (R orS)-N-((4,6- (400 MHz, DMSO-d6) δ 11.59 (br. s., 1 H), 493dimethyl-2-oxo-1,2- 7.77-7.69 (m, 1 H), 7.60 (br. s., 2 H),dihydropyridin-3- 7.06 (br. s., 2 H), 5.89 (s, 1 H), 4.31 (t, J = 5.7Hz, 2 yl)methyl)-1-(1-(1-(2- H), 4.20-4.09 (m, 1 H), 4.00-3.92 (m, 1 H),hydroxy-2- 3.58-3.55 (m, 2 H), 3.19-3.10 (m, 1 H),methylpropyl)piperidin- 3.07-2.95 (m, 1 H), 2.74-2.63 (m, 1 H), 2.59(br. 4-yl)ethyl)-2-methyl- s., 3 H), 2.27 (s, 3 H), 2.12 (s, 3 H),1H-indole-3- 1.89-1.72 (m, 1 H), 1.54 (br. s., 4 H), 1.30-1.14 (m, 2carboxamide H), 1.03 (br. s., 6 H), 0.84-0.57 (m, 2 H)

Example 6 Synthesis of (R orS)—N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-6-phenyl-1-(1-(tetrahydro-2H-pyran-4-yl)ethyl)-1H-indole-3-carboxamide(Compound 374)

A 25 mL reaction tube was charged with a magnetic stir bar, phenylboronic acid (72.6 mg, 0.596 mmol), K₃PO₄ (103 mg, 0.447 mmol), X-Phospre-catalyst(Chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2-aminoethyl)phenyl)]palladium(II))(4.92 mg, 5.96 μmol), and the vial was sealed. The vial wasevacuated/backfilled with nitrogen (3×) before the addition of methyl6-chloro-2-methyl-1-(1-(tetrahydro-2H-pyran-4-yl)ethyl)-1H-indole-3-carboxylate(Compound 314) (100 mg, 0.298 mmol) as a solution in 1,4-dioxane (1 mL).The vial was then heated to 100° C. overnight with stirring. The vialwas then allowed to cool to room temperature and the reactionconcentrated in vacuo. The crude residue was purified via SiO₂chromatography (10 g) using an eluent of ethyl acetate/hexanes (4:1) thetitle compound as a white solid (106 mg, 0.281 mmol, 94% yield).). LCMS514 (M+1)⁺; ¹H NMR ¹H NMR (400 MHz, DMSO-d₆) δ 11.59 (s, 1H), 7.98-7.84(m, 2H), 7.75-7.67 (m, 3H), 7.47 (t, J=7.8 Hz, 2H), 7.39 (d, J=8.5 Hz,1H), 7.35-7.27 (m, 1H), 6.15 (s, 1H), 4.35 (d, J=4.9 Hz, 2H), 4.25-4.12(m, 1H), 3.93 (d, J=8.5 Hz, 1H), 3.86-3.77 (m, 3H), 3.67 (d, J=8.5 Hz,1H), 3.39-3.32 (m, 1H), 3.10-3.00 (m, 1H), 2.62 (s, 3H), 2.21 (s, 3H),1.85 (d, J=10.0 Hz, 1H), 1.63-1.49 (m, 4H), 1.45-1.33 (m, 1H), 1.20-0.99(m, 1H), 0.66 (d, J=12.0 Hz, 1H).

Example 7 Synthesis of (R orS)-2-(4-(1-(3-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methylcarbamoyl)-2-methyl-1H-indol-1-yl)ethyl)piperidin-1-yl)acetic acid (Compound 364)

To a round bottomed flask was charged with a magnetic stir bar was added(R orS)-ethyl-2-(4-(1-(3-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methylcarbamoyl)-2-methyl-1H-indol-1-yl)ethyl)piperidin-1-yl)acetate(Compound 363) (69 mg, 0.132 mmol), THF (1.5 mL), MeOH (1.5 mL), andwater (0.75 mL). To this solution was added lithium hydroxidemonohydrate (5.54 mg, 0.132 mmol) and the reaction stirred at roomtemperature for 1 h. The organics were removed under reduced pressureand the resulting aqueous solution purified via reverse phase-HPLC(water/MeCN) 0→95% to afford the title compound (66 mg, 0.108 mmol, 82%yield). LCMS 514 (M+1)⁺ ¹H NMR (400 MHz, DMSO-d₆) δ=11.67 (s, 1H), 9.65(s, 1H), 7.84-7.68 (m, 2H), 7.63 (d, J=7.4 Hz, 1H), 7.14-7.03 (m, 2H),6.18 (s, 1H), 4.33 (d, J=3.6 Hz, 2H), 4.27-4.15 (m, 1H), 4.04 (br. s.,2H), 3.85 (s, 3H), 3.57 (s, 1H), 3.35-3.23 (m, 1H), 3.14-2.99 (m, 1H),2.86-2.74 (m, 1H), 2.62 (s, 3H), 2.21 (s, 3H), 2.18-2.08 (m, 1H), 1.75(s, 1H), 1.60-1.49 (m, 4H), 1.46-1.33 (m, 1H), 0.92-0.81 (m, 1H).

Example 8 Synthesis of (R or S)-methyl2-methyl-6-(pyridin-3-yl)-1-(1-(tetrahydro-2H-pyran-4-yl)ethyl)-1H-indole-3-carboxylate

This intermediate was used as an alternate starting material in Step 7set forth in Example 1 for the synthesis of other compounds of theinvention.

(R or S)-methyl2-methyl-1-(1-(tetrahydro-2H-pyran-4-yl)ethyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-3-carboxylate

To a round bottomed flask was added Pd(OAc)₂ (10.03 mg, 0.045 mmol),potassium acetate (219 mg, 2.233 mmol),4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (567 mg,2.233 mmol), and 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl(XPhos) (85 mg, 0.179 mmol), and the vial was sealed. To this vessel wasadded (R or S)-methyl6-chloro-2-methyl-1-(1-(tetrahydro-2H-pyran-4-yl)ethyl)-1H-indole-3-carboxylate(Step 6) (500 mg, 1.489 mmol) dissolved in dioxane (3.4 mL) and thereaction evacuated/back-filled with N₂ (3×) before heating to 100° C.overnight. The reaction was then allowed to cool to rt and was dilutedwith EtOAc. The reaction was filtered through diatomaceous earth and thefiltrate concentrated to afford the title compound which was used insubsequent reactions without further purification. LCMS 428 (M+1)⁺.

(R or S)-methyl2-methyl-6-(pyridin-3-yl)-1-(1-(tetrahydro-2H-pyran-4-yl)ethyl)-1H-indole-3-carboxylate

To a re-sealable vial was added K₂CO₃ (206 mg, 1.488 mmol),PdCl₂(dppf)-CH₂Cl₂ adduct (60.8 mg, 0.074 mmol), and the vial wassealed. This vial was evacuated/backfilled with N₂ (3×) before additionof (R or S)-methyl2-methyl-1-(1-(tetrahydro-2H-pyran-4-yl)ethyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-3-carboxylate(318 mg, 0.744 mmol) dissolved in 1,4-dioxane (4 mL), 3-bromopyridine(71.7 μl, 0.744 mmol), and water (400 μL). The reaction wasevacuated/backfilled with N₂ (3×) before heating to 100° C. The solutionwas cooled to room temperature and diluted with EtOAc. The solution wasfiltered and concentrated in vacuo. The crude residue was purified viasilica gel chromatography (10 g, EtOAc/hex (1:1)) to afford the titlecompound (101 mg, 0.267 mmol, 35.9% yield). LCMS 379 (M+1)⁺.

Example 9 Other Alkyl Carboxylate Intermediates

The following alkyl carboxylate intermediates were synthesized in ananalogous manner to that set forth in Step 2 of Example 1, using anappropriate starting material and reactant.

Name Structure m/z (±)-ethyl 5-fluoro-1- (1-methoxypropan-2-yl)-2-methyl-1H- indole-3-carboxylate

294 (±)-ethyl 6-fluoro-1- (1-methoxypropan-2- yl)-2-methyl-1H-indole-3-carboxylate

294 (±)-ethyl 1-(1- methoxypropan-2- yl)-2-methyl-1H-indole-3-carboxylate

276 (±)-tert-butyl 1-(1- methoxypropan-2- yl)-2-methyl-1H-pyrrolo[2,3-b] pyridine-3- carboxylate

305 (±)-tert-butyl 1-(1- ethoxypropan-2- yl)-2-methyl-1H- pyrrolo[2,3-b]pyridine-3- carboxylate

319 tert-butyl 1-(3- methoxybutan-2- yl)-2-methyl-1H- pyrrolo[2,3-b]pyridine-3- carboxylate

319 ethyl 1-(3- methoxybutan-2- yl)-2-methyl-6- (methylsulfonyl)-1H-indole-3- carboxylate

368 (±)-ethyl 1-(3- methoxypentan- 2-yl)-2-methyl- 1H-indole-3-carboxylate

304

Example 10 Other Compounds of the Invention Produced from CarboxylicAcid Intermediates

The following compounds were synthesized in an analogous manner to thatset forth in Step 4 of Example 1, using an appropriate startingmaterial. Structures of these compounds are set forth in FIG. 1.

Compound Name ¹H NMR m/z 304 (±)-1-(1-(4,4- (CDCl₃, 400 MHz) δ12.63-12.64 (d, J = 3.2 Hz, 427 difluorocyclohexyl)ethyl)- 1H), 7.84 (s,1H), 7.49 (s, 1H), N-((4-methoxy-6-methyl- 7.42-7.40 (d, J = 9.2 Hz,1H), 7.06-7.00 (m, 2H), 2-oxo-1,2-dihydropyridin- 5.90-5.89 (d, J = 3.6Hz 1H), 4.66-4.62 (t, J = 14 Hz, 3-yl)methyl)-2-methyl- 2H), 4.11-4.08(m, 1H), 3.88-3.87 (d, J = 3.6 Hz, 1H-indole-3-carboxamide 3H),2.99-2.76 (m, 3H), 2.36 (s, 1H), 2.25 (s, 3H), 2.17-2.16 (d, J = 3.2 Hz,2H), 2.08-2.05 (m, 2H), 1.84-1.70 (m, 2H), 1.61 (s, 1H), 1.51-1.47 (m,2H) 230 (±)-5-fluoro-N-((4- (400 MHz, CD₃OD) δ 7.59-7.55 (m, 1H), 416methoxy-6-methyl-2-oxo- 7.42-7.39 (m, 1H), 6.95-6.90 (m, 2H),1,2-dihydropyridin-3- 4.57 (s, 2H), 4.12 (s, 3H), 3.99-3.94 (m, 1H),yl)methyl)-1-(1- 3.72-3.65 (m, 1H), 3.19 (s, 3H), 2.64 (s, 3H),methoxypropan-2-yl)-2- 2.54 (s, 3H), 1.59-1.57 (d, 3H)methyl-1H-indole-3- carboxamide 231 (±)-6-fluoro-N-((4- (400 MHz, CD₃OD)δ 7.70-7.66 (m, 1H), 416 methoxy-6-methyl-2-oxo- 7.36-7.33 (m, 1H),6.94-6.89 (m, 2H), 1,2-dihydropyridin-3- 4.56 (s, 2H), 4.11 (s, 3H),3.97-3.92 (m, 1H), yl)methyl)-1-(1- 3.71-3.67 (m, 1H), 3.20 (s, 3H),2.62 (s, 3H), methoxypropan-2-yl)-2- 2.53 (s, 3H), 1.58-1.56 (d, 3H)methyl-1H-indole-3- carboxamide 218 (±)-N-((4-methoxy-6- (400 MHz,CD₃OD) δ 7.69 (d, J = 7.2 Hz, 398 methyl-2-oxo-1,2- 1H), 7.53 (d, J =7.6 Hz, 1H), 7.12 (m, dihydropyridin-3- 2H), 6.26 (s, 1H), 4.80 (m, 1H),4.52 (s, 2H), yl)methyl)-1-(1- 3.99 (m, 4H), 3.75 (m, 1H), 3.20 (s, 3H),methoxypropan-2-yl)-2- 2.62 (s, 3H), 2.31 (s, 3H), 1.59 (d, J = 7.2 Hz,3H) methyl-1H-indole-3- carboxamide 183 (±)-N-((4,6-dimethyl-2- (400MHz, CD₃OD) δ 7.74 (m, 1H), 382 oxo-1,2-dihydropyridin-3- 7.57 (d, J =7.6 Hz, 1H), 7.15 (m, 2H), yl)methyl)-1-(1- 6.14 (s, 1H), 4.86 (m, 1H),4.55 (s, 2H), 4.02 (m, methoxypropan-2-yl)-2- 1H), 3.77 (m, 1H), 3.22(s, 3H), 2.65 (s, 3H), methyl-1H-indole-3- 2.43 (s, 3H), 2.26 (s, 3H),1.62 (d, J = 7.2 Hz, carboxamide 3H) 204 (±)-N-((4-methoxy-6- (400 MHz,CDCl₃) δ 13.23 (s, 1H), 399 methyl-2-oxo-1,2- 8.16-8.17 (m, 1H),8.11-8.13 (m, 1H), dihydropyridin-3- 7.57-7.60 (t, J = 5.2 Hz, 1H),6.93-6.96 (m, 1H), yl)methyl)-1-(1- 5.92 (s, 1H), 4.82-4.83 (d, J = 2.4Hz, 1H), methoxypropan-2-yl)-2- 4.65-4.66 (d, J = 6.4 Hz, 2H), 3.89 (s,3H), methyl-1H-pyrrolo[2,3- 3.81-3.85 (m, 1H), 3.22 (s, 3H), 2.79 (s,3H), b]pyridine-3-carboxamide 2.17 (s, 3H), 1.64-1.66 (d, J = 8.0 Hz,3H) 211 (±)-1-(1- 379 cyclopropylethyl)-N-((4,6- dimethyl-2-oxo-1,2-dihydropyridin-3- yl)methyl)-2-methyl-1H- pyrrolo[2,3-b]pyridine-3-carboxamide 212 (±)-1-(1-ethoxypropan-2- (400 MHz, CDCl₃) δ 8.173-8.189(m, 1H), 413 yl)-N-((4-methoxy-6- 8.13-8.153 (m, 1H), 7.563 (s, 1H),methyl-2-oxo-1,2- 6.977-7.008 (m, 1H), 5.938 (s, 1H), dihydropyridin-3-4.652-4.667 (d, 2H), 4.177 (s, 1H), 3.309-3.454 (m, 2H),yl)methyl)-2-methyl-1H- 3.94-3.98 (m, 1H), 2.806 (s, 3H), 2.212 (s,pyrrolo[2,3-b]pyridine-3- 3H), 1.665-1.682 (d, 3H), 1.044 (t, 3H)carboxamide 235 (±)-N-((4-ethoxy-6- (400 MHz, CDCl₃) δ 413methyl-2-oxo-1,2- 12.5 (s, 1H), 8.11-8.18 (m, 2H), 7.60 (s,dihydropyridin-3- 1H), 6.95-6.98 (m, 1H), 5.90 (s, 1H), yl)methyl)-1-(1-5.96 (s, 1H), 4.83 (s, 1H), 4.10-4.21 (m, 3H), methoxypropan-2-yl)-2-3.82-3.83 (m, 1H), 3.23 (s, 3H), 3.79 (s, methyl-1H-pyrrolo[2,3- 3H),2.15 (s, 3H), 1.65-1.66 (d, J = 6.8 Hz, b]pyridine-3-carboxamide 6H),1.44-1.47 (t, J = 7.2 Hz, 3H). 241 N-((4,6-dimethyl-2-oxo- (400 MHz,CD₃OD): δ 8.67-8.65 (d, 1H), 397 1,2-dihydropyridin-3- 8.45-8.44 (d,1H), 7.59-7.55 (m, 1H), yl)methyl)-1-(3- 6.70 (s, 1H), 4.79 (s, 1H),4.61 (s, 2H), 4.07 (s, methoxybutan-2-yl)-2- 1H), 3.32 (s, 3H), 2.75 (s,3H), 2.56 (s, 3H), methyl-1H-pyrrolo[2,3- 2.42 (s, 3H), 1.68-1.66 (d,3H), 1.16-1.15 (d, b]pyridine-3-carboxamide 3H). 280 (±)-N-((6-ethyl-4-¹H NMR (400 MHz, CD₃OD) δ 413 methoxy-2-oxo-1,2- 8.25-8.29 (m, 2H). δ7.28-7.31 (m, 1H). 6.89 (s, 1H), dihydropyridin-3- 4.93-4.95 (br, 1H),4.58 (s, 2H), yl)methyl)-1-(1- 4.2-4.25 (m, 1H), 4.13 (s, 3H), 3.77-3.81(m, 1H), methoxypropan-2-yl)-2- 3.24 (s, 3H), 2.79-2.84 (q, 1H), 2.72(s, 3H), methyl-1H-pyrrolo[2,3- 1.66-1.68 (d, J = 7.2 Hz, 3H) 1.32-1.36(t, b]pyridine-3-carboxamide 3H) 288 (R or S)-N-((4-Methoxy- (400 MHz,d6-DMSO) δ 11.57-11.65 (m, 439 6-methyl-2-oxo-1,2- 1H), 8.18-8.23 (m,1H), 8.07-8.12 (m, dihydropyridin-3- 1H), 7.83-7.91 (m, 1H), 7.07-7.15(m, yl)methyl)-2-methyl-1-(1- 1H), 6.15 (s, 1H), 4.31 (d, J = 4.46 Hz,1H), (tetrahydro-2H-pyran-4- 4.04-4.20 (m, 1H), 3.88-3.97 (m, 1H),yl)ethyl)-1H-pyrrolo[2,3- 3.84 (s, 3H), 3.59-3.70 (m, 1H),b]pyridine-3-carboxamide 2.97-3.10 (m, 1H), 2.79-2.93 (m, 1H), 2.67 (br.S., 3H), 2.20 (s, 3H), 1.78-1.88 (m, 1H), 1.53-1.68 (m, 3H), 1.28-1.41(m, 2H), 0.97-1.13 (m, 2H), 0.56-0.68 (m, 1H) 306 (R orS)-N-((4,6-dimethyl- (400 MHz, DMSO-d₆) δ = 11.73-11.56 (m, 4232-oxo-1,2-dihydropyridin- 1 H), 8.19 (d, J = 3.1 Hz, 1 H), 8.06 (dd, J =1.4, 3-yl)methyl)-2-methyl-1- 7.9 Hz, 1 H), 7.82 (br. S., 1 H),(1-(tetrahydro-2H-pyran- 7.10 (dd, J = 4.7, 7.8 Hz, 1 H), 5.91 (s, 1 H),4-yl)ethyl)-1H-indole-3- 4.30 (br. S., 2 H), 4.19-4.02 (m, 1 H), 3.90(d, J = 8.5 Hz, carboxamide 1 H), 3.63 (d, J = 7.8 Hz, 1 H), 3.29 (s, 1H), 3.06 (s, 1 H), 2.92-2.74 (m, 1 H), 2.64 (br. S., 3 H), 2.25 (s, 3H), 2.11 (s, 3 H), 1.80 (br. S., 1 H), 1.59 (br. S., 3 H), 1.41-1.24 (m,1 H), 1.09 (s, 2 H), 0.67-0.52 (m, 1 H) 277 (±)-1-(3-methoxy-3- (400MHz, DMSO-d₆) δ = 12.01-11.82 (m, 426 methylbutan-2-yl)-N-((4- 1 H),7.91-7.82 (m, 2 H), 7.71-7.64 (m, 1 methoxy-6-methyl-2-oxo- H),7.06-6.96 (m, 2 H), 6.25 (s, 1 H), 1,2-dihydropyridin-3- 4.43 (q, J =7.1 Hz, 1 H), 4.33 (br. S., 2 H), yl)methyl)-2-methyl-1H- 3.86 (s, 3 H),3.14-3.09 (m, 3 H), 2.61 (s, 3 H), indole-3-carboxamide 2.23 (s, 3 H),1.58-1.52 (m, 3 H), 1.27 (s, 3 H), 0.88 (s, 3 H) 275(±)-N-((4,6-dimethyl-2- 410 oxo-1,2-dihydropyridin-3- yl)methyl)-1-(3-methoxypentan-2-yl)-2- methyl-1H-indole-3- carboxamide 294(±)-N-((4-methoxy-6- (CDCl₃, 400 MHz) δ 7.85 (t, J = 6.4 Hz, 412methyl-2-oxo-1,2- 1H), 7.45 (s, 2H), 7.08-7.03 (m, 2H),dihydropyridin-3- 5.93 (s, 1H), 4.71-4.61 (m, 2H), 4.36 (s, 1H),yl)methyl)-1-(3- 3.90 (s, 4H), 2.95 (s, 3H), 2.75 (s, 3H),methoxybutan-2-yl)-2- 2.17 (s, 3H), 1.57 (d, J = 7.2 Hz, 3H), 1.23 (d, J= 6.0 Hz, methyl-1H-indole-3- 3H) carboxamide 290(±)-1-(3-ethoxybutan-2- (400 MHz, DMSO-d₆) δ = 11.60 (br. s., 1 426yl)-N-((4-methoxy-6- H), 7.72 (d, J = 7.6 Hz, 1 H), 7.67 (d, J = 5.1 Hz,methyl-2-oxo-1,2- 2 H), 7.09-6.98 (m, 2 H), 6.14 (s, 1 dihydropyridin-3-H), 4.41-4.35 (m, 1 H), 4.32 (d, J = 4.9 Hz, yl)methyl)-2-methyl-1H- 2H), 4.03-3.93 (m, 1 H), 3.83 (s, 3 H), indole-3-carboxamide 3.25 (d, J =9.4 Hz, 1 H), 2.82-2.72 (m, 1 H), 2.62 (br. s., 3 H), 2.19 (s, 3 H),1.52 (d, J = 7.1 Hz, 3 H), 1.15 (d, J = 6.0 Hz, 3 H), 0.68 (t, J = 6.9Hz, 3 H) 293 N-((4-methoxy-6-methyl- (400 MHz, CDCl₃): δ 8.19-8.13 (m,2H), 427 2-oxo-1,2-dihydropyridin- 7.57-7.55 (t, 1H), 6.99-6.96 (m, 1H),3-yl) methyl)-1-(3- 5.94 (s, 1H), 4.67-4.65 (m, 2H), 4.40 (m, 1H),methoxypentan-2-yl)-2- 4.16 (m, 1H), 3.16 (s, 3H), 2.80 (s, 3H),methyl-1H-pyrrolo [2,3- 2.77 (s, 3H), 2.20 (s, 3H), 1.87-1.81 (m, b]pyridine-3-carboxamide 1H), 1.67-1.65 (m, 3H), 1.53-1.45 (m, 3H),1.02-0.99 (m, 3H) 299 N-((4-methoxy-6-methyl- (400 MHz, CDCl₃) δ7.87-7.86 (d, 1H), 425 2-oxo-1,2-dihydropyridin- 7.52-7.45 (m, 2H),7.10-7.02 (m, 2H), 3-yl)methyl)-1-(3- 4.72-4.64 (dd, 2H), 4.45-4.42 (s1H), 3.9 (s, 3H), methoxypentan-2-yl)-2- 3.73 (s, 1H), 2.8-2.7 (d, 6H),2.17 (s, 3H), methyl-1H-indole-3- 1.80-1.75 (m, 1H), 1.58 (s, 3H),carboxamide 1.25 (m, 1H), 1.03-0.99 (t, 3H)

Example 11 Synthesis of Methyl1-(1-(1,4-dioxan-2-yl)ethyl)-2-methyl-1H-indole-3-carboxylate

The title compound was used as an alternate alkyl carboxylate startingmaterial in Step 3 of Example 1.

Step 1: 1-(1,4-dioxan-2-yl)ethanone

To a solution of benzoic peroxide (20 g, 141 mmol) in 200 mL 1,4-dioxaneat room temperature under nitrogen atmosphere was added biacetyl (24.3g, 282 mmol). After the addition, the mixture was heated to reflux andstirred for 24 hours. The reaction mixture was cooled to 0° C. The pHwas adjusted to around 9 by progressively adding 2N sodium hydroxidebelow 0° C., extracted with 2-methoxy-2-methylpropane (10 mL×3), andconcentrated to give 1-(1,4-dioxan-2-yl)ethanone (13 g, 36%) as a yellowoil which was used directly in the next step without purification.

Step 2: 1-(1,4-dioxan-2-yl)ethanamine

To a solution of 1-(1,4-dioxan-2-yl)ethanone (12 g, 92.2 mmol) in1,2-dichloroethane (100 mL) was added (4-methoxyphenyl)methanamine (25g, 184.4 mmol) at room temperature. The mixture was allowed to stir for3 hours, and then sodium triacetoxyborohydride (39 g, 184.4 mmol) wasadded. The resulting mixture was allowed to stir for 48 hours at roomtemperature. The reaction mixture was quenched by adding water,extracted with dichloromethane (100 mL×3). The combined organic phasewas dried by anhydrous sodium sulphate, and then filtered. The filtratewas concentrated and purified by column chromatograph on silica gel(elute:dichloromethane/methanol 100:1→50:1→20:1) to give1-(1,4-dioxan-2-yl)-N-(4-methoxybenzyl)ethanamine (16.4 g, 71%) as ayellow solid. LCMS (M+H⁺) m/z: calcd. 251.15. found 251.9. To a solutionof 1-(1,4-dioxan-2-yl)-N-(4-methoxybenzyl)ethanamine (5 g, 19.9 mmol) inanhydrous methanol (100 mL) was added palladium 10% on carbon (240 mg, 2mmol), then purged with hydrogen (30 psi), the mixture was allowed tostir overnight at room temperature. The reaction mixture was filtered,and the filtrate was concentrated to afford the title compound (2.5 g,96%) as a brown solid.

The amine intermediates shown in the following table were preparedaccording to the general procedure outlined above using the appropriatestarting materials and modifications.

Name Structure m/z tert-butyl 3-(1-aminoethyl)piperidine- 1-carboxylate

228 (±)-1-(4,4-difluorocyclohexyl) ethanamine

164 (±)-1-(1-(methylsulfonyl)azetidin- 3-yl)ethanamine

179 (±)-tert-butyl 4-(4-(1- aminoethyl)47yridine-2-yl)piperazine-1-carboxylate

307

Step 3: (E)-methyl3-((1-(1,4-dioxan-2-yl)ethyl)imino)-2-(2-bromophenyl)butanoate

To a solution of 1-(1,4-dioxan-2-yl)ethanamine (2.5 g, 19 mmol) inmethanol (100 mL) was added methyl 2-(2-bromophenyl)-3-oxobutanoate (5.4g, 20 mmol) and acetic acid (1.8 g, 30 mmol). The resulting reactionsystem was warm to reflux and allowed to stir overnight. The reactionmixture was concentrated and purified by column chromatographed onsilica gel (eluted:dichloromethane/methanol 50:1→20:1→5:1) the titlecompound (1 g, 14%) as a brown solid. LCMS (M+H⁺) m/z: calcd. 383.07.found 384.9.

The imino-bromo intermediates shown in the following table were preparedaccording to the general procedure outlined above using the appropriatestarting materials (e.g., one of the amines set forth in the table inStep 2 of this example) and modifications.

Name Structure m/z (E)-tert-butyl 3- (1-((3-(2- bromophenyl)-4-methoxy-4- oxobutan-2- ylidene)amino) ethyl)piperidine- 1-carboxylate

482 (±)-(E)-methyl 2- (2-bromophenyl)- 3-((1-(4,4- difluoro- cyclohexyl)ethyl)imino) butanoate

417 (E)-tert-butyl 4- ((3-(2- bromophenyl)- 4-methoxy-4- oxobutan-2-ylidene)amino) piperidine-1- carboxylate

454 (Z)-methyl 2-(2- bromophenyl)-3- (quinolin-5- ylamino)but-2- enoate

398 (E)-methyl 2-(2- bromophenyl)-3- (cyclo- pentylimino) butanoate

339 (E)-methyl 2-(2- bromophenyl)-3- ((6- methylquinolin- 5-yl)imino)butanoate

412 (±)-(E)-methyl 2- (2-bromophenyl)- 3-((1-(1- (methylsulfonyl)azetidin-3- yl)ethyl)imino) butanoate

432 (±)-(E)-tert-butyl 4-(4-((3-(2- bromophenyl)-4- methoxy-4-oxobutan-2- ylidene)amino) pyridine-2- yl)piperazine-1- carboxylate

559 (E)-methyl 2-(2- bromophenyl)-3- ((2,5- dimethylphenyl) amino)but-2-enoate

375 (E)-methyl 2-(2- bromophenyl)-3- ((2,3- dimethylphenyl) amino)but-2-enoate

375 (E)-methyl 2-(2- bromophenyl)-3- (quinolin-6- ylimino)butanoate

398

Step 4: Methyl1-(1-(1,4-dioxan-2-yl)ethyl)-2-methyl-1H-indole-3-carboxylate

To a solution of (E)-methyl3-((1-(1,4-dioxan-2-yl)ethyl)imino)-2-(2-bromophenyl)butanoate (400 mg,1.1 mmol) in dioxane (3 mL) was addedChloro[2-(dicyclohexylphosphino)-3,6-dimethoxy-2′,4′,6′-triisopropylbiphenyl][2-(2-aminoethyl)phenyl]Pd(II)(160 mg, 0.2 mmol), 2-Dicyclohexyphosphino-2′,6′-diisopropoxybiphenyl(93 mg, 0.2 mmol) and sodium tert-butoxide (192 mg, 2 mmol). Theresulting reaction mixture was heated to 120° C. with stirring for 30mins in a microwave. The reaction mixture was quenched by adding waterand was extracted with ethyl acetate (25 mL×3). The combined organicphase was dried by anhydrous sodium sulphate, and then filtered. Thefiltrate was concentrated and purified by column chromatograph on silicagel (eluted:petrol ether/acetic ester 10:1→5:1→2:1) to afford the titlecompound (282 mg, 89%) as yellow solid. LCMS (M+H⁺) m/z: calcd. 303.15.found 303.9.

The compound shown in the following table was prepared according to thegeneral procedure outlined above using the appropriate startingmaterials (e.g., one of the imino-bromo intermediates shown in the tablein Step 3 of this example) and modifications.

Name Structure m/z (±)-methyl 1-(1-(4,4- difluorocyclohexyl)ethyl)-2-methyl- 1H-indole-3- carboxylate

336

These alkyl carboxylates were also used as starting material in Step 3of Example 1 in the synthesis of certain compounds of the invention.

Example 12 Chiral Separation of Compound 219 to afford Compounds 223 and224

N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-(1-methoxypropan-2-yl)-2-methyl-1H-indole-3-carboxamide(200 mg) (Compound 219) was subjected to chiral chromatography viasupercritical fluid chromatography (SFC) (A:C₂H₅OH,B:NH₃.H₂O. A:B=55:45AD column) to afford the separate enantiomers 223 (peak 1) and 224 (Peak2) (60 mg each) LCMS 398 (M+1)⁺ ¹H NMR (400 MHz, CD₃OD) δ 7.69 (d, J=7.2Hz, 1H), 7.53 (d, J=7.6 Hz, 1H), 7.12 (m, 2H), 6.26 (s, 1H), 4.80 (m,1H), 4.52 (s, 2H), 3.99 (m, 4H), 3.75 (m, 1H), 3.20 (s, 3H), 2.62 (s,3H), 2.31 (s, 3H), 1.59 (d, J=7.2 Hz, 3H). The optical rotation of eachenantiomer was not determined.

The compounds shown in the following table were prepared according tothe general chiral chromatography procedure outlined above. The opticalrotation of the separated enantiomers was not determined, but theelution peak (“Peak 1” or “Peak 2”) is indicated. Structures of eachcompound are shown in FIG. 1.

Compound Name ¹H NMR m/z 217 (R or S)-N-((4,6-dimethyl-2- (400 MHz,CD₃OD) δ 7.74 (m, 1H), 382 oxo-1,2-dihydropyridin-3- 7.57 (d, J = 7.6Hz, 1H), 7.15 (m, 2H), yl)methyl)-1-(1- 6.14 (s, 1H), 4.86 (m, 1H), 4.55(s, 2H), methoxypropan-2-yl)-2- 4.02 (m, 1H), 3.77 (m, 1H), 3.22 (s,methyl-1H-indole-3- 3H), 2.65 (s, 3H), 2.43 (s, 3H), 2.26 (s,carboxamide-PEAK 1 3H), 1.62 (d, J = 7.2 Hz, 3H) 218 (R orS)-N-((4,6-dimethyl-2- (400 MHz, CD₃OD) δ 7.74 (m, 1H), 382oxo-1,2-dihydropyridin-3- 7.57 (d, J = 7.6 Hz, 1H), 7.15 (m, 2H),yl)methyl)-1-(1- 6.14 (s, 1H), 4.86 (m, 1H), 4.55 (s, 2H),methoxypropan-2-yl)-2- 4.02 (m, 1H), 3.77 (m, 1H), 3.22 (s, 3H),methyl-1H-indole-3- 2.65 (s, 3H), 2.43 (s, 3H), 2.26 (s, 3H),carboxamide-PEAK 2 1.62 (d, J = 7.2 Hz, 3H) 252 (R or S)-(±)-1-(1- NMR(400 MHz, CDCl₃): 379 cyclopropylethyl)-N-((4,6- δ 8.32-8.34 (d, 1H),8.18-8.2 (d, 1H), dimethyl-2-oxo-1,2- 7.27-7.30 (m, 1H), 6.70 (s, 1H),4.47 (s, dihydropyridin-3-yl)methyl)- 2H), 3.94-3.95 (d, 1H), 2.61 (s,3H), 2-methyl-1H-pyrrolo[2,3- 2.43 (s, 3H), 2.29-2.30 (s, 3H),b]pyridine-3-carboxamide 1.57-1.59 (d, 3H), 0.63-0.64 (t, 1H), PEAK 10.27-0.64 (m, 2H), 0.02-0.04 (t, 1H) 253 (R or S)-(±)-1-(1- NMR (400MHz, CDCl₃): 379 cyclopropylethyl)-N-((4,6- δ 8.32-8.34 (d, 1H),8.18-8.2 (d, 1H), dimethyl-2-oxo-1,2- 7.27-7.30 (m, 1H), 6.70 (s, 1H),4.47 (s, dihydropyridin-3-yl)methyl)- 2H), 3.94-3.95 (d, 1H), 2.61 (s,3H), 2-methyl-1H-pyrrolo[2,3- 2.43 (s, 3H), 2.29-2.30 (s, 3H),b]pyridine-3-carboxamide 1.57-1.59 (d, 3H), 0.63-0.64 (t, 1H), PEAK 20.27-0.64 (m, 2H), 0.02-0.04 (t, 1H) 256 (R or S)-N-((4-methoxy-6- (400MHz, CDCl₃) δ 13.23 (s, 1H), 399 methyl-2-oxo-1,2- 8.16-8.17 (m, 1H),8.11-8.13 (m, 1H), dihydropyridin-3-yl)methyl)- 7.57-7.60 (t, J = 5.2Hz, 1H), 1-(1-methoxypropan-2-yl)-2- 6.93-6.96 (m, 1H), 5.92 (s, 1H),4.82-4.83 (d, J = 2.4 Hz, methyl-1H-pyrrolo[2,3- 1H), 4.65-4.66 (d, J =6.4 Hz, b]pyridine-3-carboxamide 2H), 3.89 (s, 3H), 3.81-3.85 (m, 1H),PEAK 1 3.22 (s, 3H), 2.79 (s, 3H), 2.17 (s, 3H), 1.64-1.66 (d, J = 8.0Hz, 3H) 257 (R or S)-N-((4-methoxy-6- (400 MHz, CDCl₃) δ 13.23 (s, 1H),399 methyl-2-oxo-1,2- 8.16-8.17 (m, 1H), 8.11-8.13 (m, 1H),dihydropyridin-3-yl)methyl)- 7.57-7.60 (t, J = 5.2 Hz, 1H),1-(1-methoxypropan-2-yl)-2- 6.93-6.96 (m, 1H), 5.92 (s, 1H), 4.82-4.83(d, J = 2.4 Hz, methyl-1H-pyrrolo[2,3- 1H), 4.65-4.66 (d, J = 6.4 Hz,b]pyridine-3-carboxamide 2H), 3.89 (s, 3H), 3.81-3.85 (m, 1H), PEAK 23.22 (s, 3H), 2.79 (s, 3H), 2.17 (s, 3H), 1.64-1.66 (d, J = 8.0 Hz, 3H)307 Trans-(R or S, R or S)—N-((4- (CDCl₃, 400 MHz) δ 7.85 (t, J = 6.4Hz, 412 methoxy-6-methyl-2-oxo-1,2- 1H), 7.45 (s, 2H), 7.08-7.03 (m,dihydropyridin-3-yl)methyl)- 2H), 5.93 (s, 1H), 4.71-4.61 (m, 2H),1-(3-methoxybutan-2-yl)-2- 4.36 (s, 1H), 3.90 (s, 4H), 2.95 (s, 3H),methyl-1H-indole-3- 2.75 (s, 3H), 2.17 (s, 3H), 1.57 (d, J = 7.2 Hz,carboxamide 3H), 1.23 (d, J = 6.0 Hz, 3H) PEAK 1 308 Trans-(R or S, R orS)—N-((4- (CDCl₃, 400 MHz) δ 7.85 (t, J = 6.4 Hz, 412methoxy-6-methyl-2-oxo-1,2- 1H), 7.45 (s, 2H), 7.08-7.03 (m,dihydropyridin-3-yl)methyl)- 2H), 5.93 (s, 1H), 4.71-4.61 (m, 2H),1-(3-methoxybutan-2-yl)-2- 4.36 (s, 1H), 3.90 (s, 4H), 2.95 (s, 3H),methyl-1H-indole-3- 2.75 (s, 3H), 2.17 (s, 3H), 1.57 (d, J = 7.2 Hz,carboxamide 3H), 1.23 (d, J = 6.0 Hz, 3H) PEAK 2

Example 1 Synthesis of tert-butyl1-(2,3-dihydro-1H-inden-1-yl)-2-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxylate

The title compound as starting material in Step 3 of Example 36 in thesynthesis of certain compounds of the invention.

Tert-butyl 2-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxylate

To a 500 mL round-bottom flask that containsN-acetyl-N-(3-bromopyridin-2-yl)acetamide (14.815 g, 57.6 mmol), wasadded copper(I) iodide (1.098 g, 5.76 mmol), L-proline (1.327 g, 11.53mmol), cesium carbonate (28.2 g, 86 mmol), then t-butyl acetoacetate(11.47 ml, 69.2 mmol) and dioxane (100 mL). The reaction was vac/purgedwith N₂ 3× then fitted with a septum and a N₂ inlet and heated overnightat 70° C. The inorganic solids were removed by filtration over celiteand the cake was washed with 100 mL EtOAc. This solution wasconcentrated and the residue was partitioned between 250 mL brine and250 mL EtOAc. The aq. Layer was further extracted with EtOAc (2×250 mL)and the combined organic layer was dried over Na₂SO₄, filtered,concentrated and purified by CC using 1:1 EtOAc:Hex as eluent to provide(2.7 g, 20.2%) of tert-butyl2-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxylate. LRMS (M+H⁺) m/z:calc'd 233.28. found 233.1.

Tert-butyl1-(2,3-dihydro-1H-inden-1-yl)-2-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxylate

A solution of ethyl tert-butyl2-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxylate (100 mg, 0.74 mmol),2,3-dihydro-1H-inden-1-ol (176 mg, 0.74 mmol), PPh₃ (195 mg, 1.49 mmol)was stirred in dry THF (10 mL) at 0° C. under a nitrogen atmosphere. Tothis mixture was added drop-wise DIAD (150 mg, 1.48 mmol) over a periodof 5 min, and the reaction was stirred at room temperature for 16 hours.The mixture was washed with brine, dried and concentrated to afford thecrude product. The crude product was purified by silica gelchromatography (petroleum ether/ethyl acetate=5:1) to afford thetert-butyl-1-(2,3-dihydro-1H-inden-1-yl)-2-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxylate(150 mg, 60%).

The compound shown in the following table was prepared according to thegeneral procedure outlined above using the appropriate startingmaterials and modifications.

Name Structure m/z (±)-tert-butyl 1-(1- cyclopropylethyl)-2-methyl-1H-pyrrolo[2,3-b]pyridine- 3-carboxylate

301

Each of the above alkyl carboxylates was used as starting material inStep 3 of Example 1 in the synthesis of certain compounds of theinvention.

Example 13 Synthesis of isolatedN-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-((2R or2S, 3R or3S)-3-methoxybutan-2-yl)-2-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxamidediastereomers (Compounds 261, 266, 267 and 302) Step 1: Tert-butyl2-methyl-1-(3-oxobutan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboxylate

To a solution of tert-butyl2-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxylate (5.0 g, 21.53 mmol) inCH₃CN (50 mL) was added Cs₂CO₃ (21.0 g, 64.58 mmol), potassium iodide(3.57 g, 21.53 mmol). The mixture was stirred at 27° C. for 30 minutes.Then 3-chlorobutan-2-one (2.75 g, 25.83 mmol) was added and the mixturewas stirred at 70° C. for 12 hours. The mixture was filtered and thefiltrate was concentrated. The residue was purified by column(Elute:Petroleum ether:Ethyl acetate 50:1) to give tert-butyl2-methyl-1-(3-oxobutan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboxylate asa yellow-green oil. (3.23 g, yield 50%) LCMS (M+H⁺) m/z: calcd 303.37.found 302.9. 1H NMR (400 MHz, CDCl₃): ä 8.32-8.30 (m, 1H), 8.25-8.23 (m,1H), 7.17-7.14 (m, 1H), 5.50-5.44 (m, 1H), 2.71 (s, 3H), 1.96 (s, 3H),1.65-1.67 (d, 3H), 1.64 (s, 9H).

Step 2: Tert-butyl1-(3-hydroxybutan-2-yl)-2-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxylate

To the solution of tert-butyl2-methyl-1-(3-oxobutan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboxylate(3.1 g, 10.25 mmol) in methanol (30 mL) was added sodium borohydride(0.30 g, 8.2 mmol) at 0° C. After 30 minutes, another batch of sodiumborohydride (0.30 g, 8.2 mmol) was added at 0° C. After the reactioncompleted about 2 h later, water (30 ml) was added dropwise verycarefully to quench the reaction. The mixture was extracted with CH₂Cl₂.The extraction was dried over Na₂SO₄, filtered and concentrated undervacuum to give tert-butyl1-(3-hydroxybutan-2-yl)-2-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxylateas a yellow solid. (3.0 g, yield 96%) LCMS (M+H⁺) m/z: calcd 305.38.found 304.9. 1H NMR (400 MHz, CDCl₃): ä 8.31-8.29 (m, 1H), 8.13-8.12 (m,1H), 7.11-7.07 (m, 1H), 4.46-4.43 (m, 1H), 4.12 (m, 1H), 2.73 (s, 3H),1.58 (s, 9H), 1.51-1.49 (d, 3H), 0.92-0.91 (d, 3H).

Step 3:Tert-butyl-1-(3-methoxybutan-2-yl)-2-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxylate

To dry THF (20 mL) was added NaH (60% in mineral oil, 2.37 g, 59.14mmol). Then the mixture was stirred at 27° C. for 20 minutes, thentert-butyl1-(3-hydroxybutan-2-yl)-2-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxylate(3.0 g, 9.86 mmol) was added. The mixture was stirred at 27° C. for 1hour, then added by CH₃I (13.99 g, 98.6 mmol). The mixture was stirredfor 12 hours at 27° C. and then cooled to 0° C. Sat. NH₄Cl was added andextracted with CH₂Cl₂. The extraction was dried over sodium sulfate,filtered and concentrated to givetert-butyl-1-(3-methoxybutan-2-yl)-2-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxylateas a yellow oil. (3.2 g, yield 100%) LCMS (M+H⁺) m/z: calcd. 319.41.found 318.9.

Step 4:1-(3-methoxybutan-2-yl)-2-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxylicacid

To the pre-cooled solution of tert-butyl1-(3-methoxybutan-2-yl)-2-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxylate(3.0 g, 9.42 mmol) in CH₂Cl₂ (20 mL) was added trifluoroacetic acid (20mL) dropwise. The solution was stirred at 27° C. for 1.5 hours. Thesolvent was removed under vacuum at 27° C. The residue was used for nextstep without purified. LCMS (M+H+) m/z: calcd 263.30. found 262.9.

Step 5:N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-(3-methoxybutan-2-yl)-2-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxamide

To a solution of1-(3-methoxybutan-2-yl)-2-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxylicacid (2.4 g, 9.15 mmol) in DMF (30 mL) was added TEA (4.2 g, 41.50mmol), 3-(aminomethyl)-4-methoxy-6-methylpyridin-2(1H)-one hydrochloride(2.1 g, 12.81 mmol) After stirred for 10 minutes at 27° C., the mixturewas cooled and added HATU (5.56 g, 14.64 mmol). The mixture was stirredat 27° C. for 72 hours and 30% of S.M. remained. Then the mixture washeated at 80° C. for 5 hours. The solution was diluted with brine (100mL) and extracted with CH₂Cl₂ (100 mL*3). The extractions were combinedand dried over Na₂SO₄. The solvent was evaporated under vacuum and theresidue was purified by flash column (Eluent:dichloromethane:methanol95:5) to giveN-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-(3-methoxybutan-2-yl)-2-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxamide.(3.6 g, yield 95%)

Step 6: Separation ofN-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-(3-methoxybutan-2-yl)-2-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxamide:Isomers (Compounds 261, 266, 267, and 302)

The mixture of isomers from Step 5,N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-(3-methoxybutan-2-yl)-2-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxamidewas purified by prep-HPLC (Condition: Column: SHIMADZU LC-8A, 250*50mm*10 um; Mobile phase A: water with 0.2% formic acid; Mobile phase B:MeCN; column temperature: 30° C.; Gradient: B in A 10-50%) to give amajor isomer pair (Compound 261 and Compound 266 combined) (1.0 g,purity 98.8%) and a minor isomer pair (Compound 267 and Compound 302combined) (180 mg, purity 63%). The resulting isomer pairs wereindividually separated by SFC (Condition: Column: Chiralpak AD 250*30mm*5 um; Mobile phase A: Supercritical CO₂; Mobile phase B: IPA+NH₃.H₂O;Gradient: B/A: 75:25) to give the following individual single compounds:

Compound 261,N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-((2R or2S, 3R or3S)-3-methoxybutan-2-yl)-2-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxamide(Major Isomer Pair; Peak 1): ¹H NMR (400 MHz, CDCl₃): δ 8.173-8.157 (m,1H), 8.140-8.116 (m, 1H), 7.582-7.555 (m, 1H), 6.968-6.936 (m, 1H),5.927 (s, 1H), 4.707-4.609 (m, 2H), 4.348 (s, 1H), 3.892 (s, 3H), 2.869(s, 3H), 2.788 (s, 3H), 2.173 (s, 3H), 1.644-1.627 (d, 3H), 1.263-1.249(d, 3H).

Compound 266,N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-((2R or2S, 3R or3S)-3-methoxybutan-2-yl)-2-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxamide(Major Isomer Pair; Peak 2): ¹H NMR (400 MHz, CDCl₃): δ 8.179-8.163 (m,1H), 8.143-8.120 (m, 1H), 7.558-7.531 (m, 1H), 6.986-6.954 (m, 1H),5.931 (s, 1H), 4.702-4.605 (m, 2H), 3.897 (s, 3H), 2.892 (s, 3H), 2.789(s, 3H), 2.189 (s, 3H), 1.647-1.629 (d, 3H), 1.267-1.252 (d, 3H).

Compound 267,N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-((2R or2S, 3R or3S)-3-methoxybutan-2-yl)-2-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxamide(Minor Isomer Pair; Peak 1): ¹H NMR (400 MHz, CDCl₃): δ 8.174-8.162 (d,1H), 8.111-8.094 (d, 1H), 7.551-7.526 (m, 1H), 6.993-6.961 (m, 1H),5.935 (s, 1H), 4.683-4.579 (m, 2H), 3.887 (s, 3H), 3.442 (s, 3H), 2.753(s, 3H), 2.194 (s, 3H), 1.695-1.678 (d, 3H), 0.781-0.768 (d, 3H).

Compound 302,N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-((2R or2S, 3R or3S)-3-methoxybutan-2-yl)-2-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxamide(Minor Isomer Pair; Peak 2): ¹H NMR (400 MHz, CDCl₃): δ 8.177-8.166 (d,1H), 8.122-8.104 (d, 1H), 7.587-7.562 (m, 1H), 6.984-6.952 (m, 1H),5.933 (s, 1H), 4.698-4.591 (m, 2H), 4.426 (s, 2H), 3.983 (s, 3H), 3.448(s, 3H), 2.764 (s, 3H), 2.180 (s, 3H), 1.701-1.684 (d, 3H), 0.786-0.772(d, 3H).

Example 14 Synthesis of(±)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-phenylethyl)-1H-pyrrolo[2,3-c]pyridine-3-carboxamideStep 1: 1-(3-methoxyphenyl)ethanol

To a stirred solution of 3-Amino-4-picoline (7 g, 64.8 mmol) inanhydrous THF (200 mL), sec-BuLi (150 mL, 1.3M in cyclohexane, 194 mmol)was added dropwise over 20 minutes at −78° C. The solution was warmed toroom temperature and stirred at 3 hours. Ethyl acetate (2.3 g, 25.9mmol) was added dropwise into the reaction at −78° C. and the mixturewas stirred at the same temperature for 2 hours. Methanol (50 mL) wasadded dropwise into the reaction over 10 minutes. The mixture was warmedto room temperature and stirred for 1 hour. A half-saturated NH4Cl (250mL) was added. The mixture was extracted with EA. The combined organiclayers were washed with brine, dried and concentrated to afford thecrude product. The crude product was purified by silica gelchromatography (petroleum ether/ethyl acetate=10:1) to afford2-methyl-1H-pyrrolo[2,3-c]pyridine (2.5 g, 73.5%).

Step 2:2,2,2-trichloro-1-(2-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl)ethanone

To a stirred solution of 2-methyl-1H-pyrrolo[2,3-c]pyridine (2.5 g, 18.9mmol) and aluminum chloride (5 g, 37.8 mmol) in DCM (100 mL),trichloroacetylchloride (4.1 g, 22.7 mmol) was added dropwise into thereaction over 0.5 hours at room temperature. After stirring 2 hours, thereaction was cooled to 0° C. and was quenched with water (100 mL). Theresulting precipitate was isolated by filtration to afford2,2,2-trichloro-1-(2-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl)ethanone whichwas used for next step without further purification. Assumed 100% yield.(5.24 g).

Step 3: Methyl 2-methyl-1H-pyrrolo[2,3-c]pyridine-3-carboxylate

A mixture of2,2,2-trichloro-1-(2-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl)ethanone (5.24g, 18.9 mmol) and KOH (1.2 g, 20.9 mmol) in MeOH (100 mL) was stirred atroom temperature for 16 hour. The reaction mixture was concentrated toremove MeOH, the residue was partitioned between EA and Water. Theorganic layer was washed with brine, dried and concentrated to affordmethyl 2-methyl-1H-pyrrolo[2,3-c]pyridine-3-carboxylate (3 g, 83%).

Step 4: Methyl methyl2-methyl-1-(1-phenylethyl)-1H-pyrrolo[2,3-c]pyridine-3-carboxylate

A mixture of methyl 2-methyl-1H-pyrrolo[2,3-c]pyridine-3-carboxylate(550 mg, 2.89 mmol) and sodium hydride (200 mg, 4.34 mmol) inN,N-dimethylformamide (3.0 mL) was stirred at room temperature for 0.5hour, and then (1-bromoethyl)benzene (589 mg, 3.18 mmol) was added. Themixture was stirred at room temperature for 3 hours. The reactionmixture was poured into saturated NH₄Cl and extracted with ethylacetate. Organic layers were combined and concentrated to give aresidue. The residue was purified by chromatography (petroleumether/ethyl acetate=5:1) to give methyl2-methyl-1-(1-phenylethyl)-1H-pyrrolo[2,3-c]pyridine-3-carboxylate (800mg, 94%).

Step 5:2-methyl-1-(1-phenylethyl)-1H-pyrrolo[2,3-c]pyridine-3-carboxylic acid

To a mixture of methyl2-methyl-1-(1-phenylethyl)-1H-pyrrolo[2,3-c]pyridine-3-carboxylate (800mg, 2.72 mmol) and KOH (1.5 g, 27.2 mmol) in (15 mL) and water (5 mL)was refluxed for 2 hours. The mixture was adjust PH to 2 by 10% HCl andextracted with EA. The combined organic layers were washed with brine,dried and concentrated to afford the crude product. The crude productwas used into the next step without more purification. 100% yield. (760mg).

Step 6:(±)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-phenylethyl)-1H-pyrrolo[2,3-c]pyridine-3-carboxamide(Compound 203)

A mixture of2-methyl-1-(1-phenylethyl)-1H-pyrrolo[2,3-c]pyridine-3-carboxylic acid(280 mg, 1.0 mmol) was added HATU (456 mg, 1.2 mmol), TEA (1 g, 10 mmol)and 3-(aminomethyl)-4,6-dimethylpyridin-2(1H)-one (182 mg, 1.2 mmol) inanhydrous dichloromethane (30 mL) was stirred at room temperature for 16hours. To the reaction mixture was added water (10 mL), extracted withdichloromethane (30 mL×2). The organic layers were combined andconcentrated to give a residue. The residue was rereystallized from MeCNto afford compoundN-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-phenylethyl)-1H-pyrrolo[2,3-c]pyridine-3-carboxamideas an off-white solid (80 mg, 21.6%). LRMS (M+H) m/z: calcd 414.21.found 414. ¹H NMR (400 MHz, Methanol-d4) δ: 8.84 (s, 1H), 8.16 (d, J=7.6Hz, 1H), 8.03 (d, J=6.8 Hz, 1H), 7.44-7.37 (m, 5H), 6.09 (s, 1H),6.01-5.99 (m, 1H), 4.49 (s, 2H), 2.73 (s, 3H), 2.38 (s, 3H), 2.22 (s,3H), 2.06 (d, J=7.2 Hz, 3H).

The compounds shown in the following table were prepared according tothe general procedure outlined in this example using the appropriatestarting materials and modifications. Structures are shown in FIG. 1.

Compound Name NMR m/z 240 (±)-N-((4,6-dimethyl-2- (400 MHz,CHLOROFORM-d) δ ppm 383 oxo-1,2-dihydropyridin- 1.63 (br. s., 3 H) 2.21(s, 3 H) 2.41 (s, 3 H) 2.73 (s, 3-yl)methyl)-1-(1- 3 H) 3.24 (s, 3 H)2.72 (dd, J = 9.81, 5.40 Hz, methoxypropan-2-yl)-2- 1 H) 3.80-3.88 (m, 1H) 4.60 (d, J = 5.95 Hz, methyl-1H-pyrrolo[2,3- 2 H) 4.71 (dd, J =13.23, 7.06 Hz, 1 H) 5.92 (s, c]pyridine-3- 1 H) 7.31 (d, J = 5.73 Hz, 1H) 7.38 (br. s., 1 carboxamide H) 8.26 (d, J = 5.29 Hz, 1 H) 9.09 (br.s., 1 H) 11.07 (br. s., 1 H) 243 (±)-N-((4-methoxy-6- (400 MHz,CHLOROFORM-d) δ ppm 431 methyl-2-oxo-1,2- 1.62 (br. s., 3 H) 2.26 (s, 3H) 2.75 (s, 3 H) 3.25 (s, dihydropyridin-3- 3 H) 3.72 (dd, J = 9.81,5.40 Hz, 1 H) yl)methyl)-2-methyl-1- 3.80-3.87 (m, 1 H) 3.90 (s, 3 H)4.65 (d, J = 5.29 Hz, (1-phenylethyl)-1H- 2 H) 4.71 (dd, J = 13.78, 6.95Hz, 1 H) pyrrolo[2,3-c]pyridine- 5.93 (s, 1 H) 7.32 (br. s., 1 H) 7.50(br. s., 1 3-carboxamide H) 8.25 (br. s., 1 H) 9.11 (br. s., 1 H)

Example 15 General Procedures for Synthesizing Other Compounds of theInvention General Procedure A Indole Alkyation

To a cooled (0° C.) solution of NH indole ester (1 equivalent) inN,N-dimethylformamide (volume to make concentration 0.4M) was addedsodium hydride (60% w/w, 1.1 equivalents relative to indole). Theresultant mixture was stirred for 15 minutes. Then RX (2 equivalents)was added and the reaction was allowed to warm to room temperature. Thereaction was maintained at ambient temperature for 12 hours. Thereaction mixture was poured into saturated ammonium chloride solution(100 mL) with stirring. The mixture was extracted with ethyl acetate(200 mL×2) and the combined organic phase was washed with brine, driedover magnesium sulfate, filtered, and concentrated to give crude productwhich was purified by column chromatography (silica gel, petroleumether/ethyl acetate=20:1) to afford the desired alkylated Indole esterproduct.

General Procedure B Saponification of Alkylated Indole Ester

To a solution of alkylated Indole ester (1 equivalent) intetrahydrofuran:methanol:water (2.5:5:1, volume to make concentration0.05M) was added lithium hydroxide (4 equivalents). The resultantreaction mixture was stirred at 60° C. for 48 hours. The mixture wasconcentrated in vacuo. Then the residue was diluted with water (40 mL)and slowly acidified with 1N hydrogen chloride to pH=4-5. The mixturewas extracted with ethyl acetate (100 mL×3). The combined organic layerswere washed with brine, dried over magnesium sulfate, filtered andconcentrated to give crude indole acid, which was used in the subsequentstep without additional purification.

General Procedure C Amide Bond Formation

To a solution of Indole acid (1 equivalent) in dichloromethane (volumeto make concentration 0.05M) were added 1-hydroxybenzotriazole (1.5equivalents), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimidehydrochloride (1.5 equiv.) and triethylamine (3 equiv.). The resultantmixture was stirred at room temperature for 30 minutes. Then Pyridoneamine (1.2 equiv.) was added and the resultant mixture was stirred atroom temperature for 16 hours. Water (50 mL) was added to the mixture.The mixture was extracted with dichloromethane (100 mL×2). The organiclayer was concentrated in vacuo to provide crude product which waspurified by column chromatography (silica gel,dichloromethane/methanol=20:1) to afford the target compound.

General Procedure D Chiral Chromatography

Separation of chiral compounds was accomplished via normal phase HPLC orSFC (supercritical carbon dioxide fluid chromatography). Separatedcompounds were typically >95% ee. The absolute configuration of chiralcenters was not determined.

General Procedure L Sulphonylation

To a solution of Chiral amine (1 equiv.) in dichloromethane (volume tomake concentration 0.1M) was added triethylamine (4 equiv.) at 18° C.under N₂. The reaction was cooled to 0° C. and methanesulfonyl chloride(1.5 equiv.) was added. The reaction was stirred at 0° C. for 1 h. Thenthe mixture was concentrated in vacuo and methanol and potassiumcarbonate were added and the reaction was stirred for another 1 h. Themixture was filtered and the crude product was purified bypreparative-HPLC.

The table below lists compounds of the invention and which of the abovegeneral methods was used in their synthesis. Structures of thesecompounds are set forth in FIG. 1.

General Methods Compound Used and Notes Name NMR data m/z 370 General ¹HNMR (CDCl3, 400 MHz) 517 procedure L on δ 12.12 (s, 1H), 9.20 (s, 1H),(±)-N-((4- 8.78 (s, 1H), 7.68 (s, 1H), methoxy-6- 5.97 (s, 1H),4.70-4.58 (m, methyl-2-oxo- 2H), 3.91 (s, 4H), 3.62 (d, J = 12.0 Hz,1,2- 1H), 2.76-2.67 (m, dihydropyridin- 7H), 2.45 (dd, J₁ = 2.0 Hz, J₂ =11.6 Hz, 3-yl)methyl)-6- 1H), 2.32 (s, 3H), methyl-7-(1- 2.10 (t, J =12.0 Hz, 1H), (piperidin-4- 1.67 (d, J = 6.8 Hz, 4H), yl)ethyl)-7H-1.48-1.40 (m, 1H), pyrrolo[2,3- 1.37-1.29 (m, 1H), 1.27-1.19 (m, 1H),d]pyrimidine-5- 0.9-0.78 (m, 1H). carboxamide

Example 16 IC₅₀ Measurements for Inhibitors Using EZH2

EZH2 Assay:

Assays were carried out by mixing rPRC2 together with biotinylatedoligonucleosome substrates in the presence of the radio-labeled enzymeco-factor, S-adenosyl-L-methionine (³H SAM) (Perkin Elmer) andmonitoring the enzymatically mediated transfer of tritiated methylgroups from ³H SAM to histone lysine residues. The amount of resultingtritiated methyl histone product was measured by first capturing thebiotinylated oligonucleosomes in streptavidin (SAV) coated FlashPlates(Perkin Elmer), followed by a wash step to remove un-reacted ³H SAM, andthen counting on a TopCount NXT 384 well plate scintillation counter(Perkin Elmer). The final assay conditions for EZH2 were as follows: 50mM Tris Buffer pH 8.5, 1 mM DTT, 69 μM Brij-35 detergent, 5.0 mM MgCl₂,0.1 mg/mL BSA, 0.2 μM ³H SAM, 0.2 μM biotinylated oligonucleosomes, 3.6μM H3K27me3 peptide and 2 nM EZH2.

Compound IC₅₀ measurements were obtained as follows: Compounds werefirst dissolved in 100% DMSO as 10 mM stock solutions. Ten point doseresponse curves were generated by dispensing varying amounts of the 10mM compound solution in 10 wells of the 384 well plate (Echo; Labcyte),pure DMSO was then used to backfill the wells to insure all wells havethe same amount of DMSO. A 12.5 μL volume of the HMT enzyme, H3K27me3peptide and oligonucleosome substrate in assay buffer was added to eachwell of the assay plate using a Multidrop Combi (ThermoFisher).Compounds were pre-incubated with the enzyme for 20 min, followed byinitiation of the methyltransferase reaction by addition of 12.5 μL of³H SAM in assay buffer (final volume=25 μL). The final concentrations ofcompounds ranged from a top default concentration of 80 μM down to 0.16μM in ten 2-fold dilution steps. Reactions were carried out for 60minutes and quenched with 20 μL per well of 1.96 mM SAH, 50 mM Tris pH8.5, 200 mM EDTA. Stopped reactions were transferred to SAV coatedFlashplates (Perkin Elmer), incubated for 120 min, washed with a platewasher, and then read on the TopCount NXT (1.0 min/well) to measure theamount of methyl histone product formed during the reaction. The amountof methyl histone product was compared with the amount of product formedin the 0% and 100% inhibition control wells allowing the calculation of% Inhibition in the presence of the individual compounds at variousconcentrations. IC₅₀'s were computed using a 4 parameter fit non-linearcurve fitting software package (XLFIT, part of the database package,ActivityBase (IDBS)) where the four parameters were IC₅₀, Hill slope,pre-transitional baseline (0% INH), and post-transitional baseline (100%INH); with the latter two parameters being fixed to zero and 100%,respectively, by default.

Assay for Y641N EZH2 was performed as above using reconstituted H3K27Me2oligonucleosomes as substrate.

Table 2 shows the activity of selected compounds of this invention inthe EZH2 and Y641N EZH2 activity inhibition assay. IC₅₀ values arereported as follows: “A” indicates an IC₅₀ value of less than 100 nM;“B” indicates an IC₅₀ value of 100 nM to 1 μM; “C” indicates an IC₅₀value of greater than 1 μM and less than 10 μM for each enzyme; “D”indicates an IC₅₀ value of greater than 10 μM for each enzyme; and “*(XμM)” indicates that no inhibition was observed at the highestconcentration (i.e., X μM) of compound tested.

TABLE 2 IC50 Values for Compounds of Formula I against EZH2 and Y641NEZH2 Mutant Enzymes. Compound Y641N No. EZH2 IC₅₀ EZH2 IC₅₀ 183 A A 204A B 211 A B 212 A B 217 B B 218 A A 219 A A 223 A B 224 A A 229 C D 230A B 231 A B 234 C D 235 B C 236 *(0.5 μM) *(10 μM) 240 A B 241 A B 243 AB 252 A B 253 A B 256 A B 257 B C 261 A A 266 B B 267 A B 273 A A 275 AA 277 A A 280 B C 284 A B 288 A A 290 A B 293 A B 294 A A 298 A A 299 AA 300 A A 302 B C 304 A A 306 A A 307 A A 308 B B 310 A A 313 A A 314 AA 316 A A 317 A A 321 A A 327 A A 335 A A 336 A A 337 A A 341 A A 342 AA 343 A A 344 A A 345 A A 346 A A 347 A A 352 A A 355 A A 356 A A 357 AA 358 A A 359 A A 360 A A 362 A A 363 A A 364 A B 365 A A 366 A A 367 AA 368 A A 369 A A 370 A A 373 A A 375 A A 376 A A 377 A A

Example 17 EC50 Measurements for Inhibitors in HeLa Cell Assays

H3K27me3 MSD Hela Assay.

Trypsinized HeLa cells were counted and diluted in 10% DMEM (LifeTechnologies, Cat. #10569) to 5000 cells/75 μL. Seventy-five μL of cellswere place in each well of a 96-well flat-bottomed plate and incubatedat 37° C. for 4 hours. Twenty-five μL of test compound (at variousconcentrations) was added to the cells and incubation continued at 37°C. for 96 hours. Media was then removed and the cells rinsed once withice cold PBS. Forty μL of ice-cold MSD Buffer AT (10 mM HEPES, pH 7.9, 5mM MgCl₂, 0.25M sucrose, Benzonase (1:10000), 1% Triton X-100supplemented with fresh 1× Protease Inhibitor cocktail and 1 mM4-(2-Aminoethyl)benzenesulfonyl fluoride hydrochloride (AEBSF)) wasadded to each well and the plates placed on ice for 30 minutes. Ten μLof 5M NaCl was then added to each well and incubation on ice continuedfor another 15 minutes. The material in each well was suspendedpipetting up and down and then transferred to a new 96 well plate. Theemptied wells were rinsed with 150 uL ice-cold 20 mM Tris pH 7.5, 1 mMEDTA, 1 mM EGTA, supplemented with fresh 1× Protease Inhibitor cocktailand 1 mM AEBSF (“NO salt NO detergent buffer) and transferred to therespective wells in the new plate. Three hundred μL of NO Salt NOdetergent buffer was then added to each well of lysates and the platesfrozen at −80° C.

On the same day, an appropriate number of MSD standard bind 96-wellplates were coated with 30 μL/well of total H3 capture antibody(Millipore, Cat # MAB3422) at 1 μg/mL concentration in PBS. The antibodysolution was evenly distributed first by tapping gently on the sides ofthe plates and then by shaking the plates for a few minutes at 1000 rpm.Antibody coated plates were stored at 4° C. overnight.

The next day the lysates are thawed to RT. The antibody coated MSDplates are washed 3× with TBS-T (Tris-buffered saline (FisherScientific, Cat #BP2471-1)+0.2% Tween-20). One-hundred fifty μL of 5%Blocker A in TBS-T is added to each well. The wells are covered andshaken on a shaker at RT for one hour. The Blocker A step is repeated asecond time. After removing the blocker, 25 μL of cell lysate istransferred into each antibody coated well. The plates are shaken for 2hours at RT, the lysate removed and the plates again washed with BlockerA in TBS-T. Twenty-five μL of appropriate freshly prepared antibody mix(including both primary and secondary antibodies) is added to each welland the plates shaken for 1 hour at RT. The antibody mix used was one(or both) of those indicated in the table below:

Anti-rabbit Concentration Primary detection 1% blocker A Ab (μg/mL) Ab(μL) Ab (μL) (μL) H3K27me3 33 37.88 5.00 5000 H3 12 52.08 5.00 5000Both H3 antibodies were obtained from Cell Signalling (Cat #s 4499 and9733). The goat anti-rabbit antibody was obtained from Meso-ScaleDiscovery (Cat #R32AB-1).

The antibody mix was then removed and the wells washed with Blocker A.One hundred-fifty μL of freshly prepared 1×MSD Read Buffer (Meso-ScaleDiscovery; Cat #R927C-2) was then added to each well and the plates readon a MSD Sector 2400 Plate Reader.

Data was analyzed using Assay Assistant (Constellation PharmaceuticalsIn-house product) and Activity Base (IDBS Ltd, Surrey, UK) template.Data files were imported to Assay Assistant and assay conditions werespecified. A unique Analysis ID was created and the data files exportedto Activity Base. An analysis template was created on Activity Base tomeasure dose-dependent inhibition of H3K27me3 mark and cell viabilityrespectively. Readout of DMSO wells were used to normalize the data.Resulting curves were fitted using Activity base software Model 205(IDBS Ltd, Surrey, UK). The data was checked for quality, validated andintegrated in excel format using SARview (IDBS Ltd, Surrey, UK).

H3K27me3 Alpha Hela Assay (AlphaLISA).

Ten different doses of each test compound (in a series of 3-folddilutions) were plated in duplicate 384-well tissue culture treatedplates (Catalog #781080; Greiner Bio One; Monroe, N.C.). Hela cellsgrown in culture were trypsinized and counted using a Countess® cellcounter (Catalog #C10281; Life Technologies, Grand Island, N.Y.). Cellwere diluted to 67,000 cells per mL in 10% DMEM (Catalog #10569-010 LifeTechnologies, Grand Island, N.Y.) and 15 μL (1,000 cells) were platedinto each well using the Biotek MicroFlo™ Select Dispenser (BioTekInstruments, Inc. Vermont, USA),) of the 384-well plate. Plates wereincubated at 37° C./5% CO₂ for 72 hrs. One of the duplicate plates wasprocessed for HeLa assay and the other for viability.

To the plate processed for AlphaLISA was added 5 μL per wellCell-Histone Lysis buffer (1×) (Catalog # AL009F1 Perkin Elmer; Waltham,Mass.) and the plate was incubated at RT for 30 minutes on a plateshaker with low speed (Model#4625-Q Thermo Scientific; Waltham, Mass.).Then, 10 μL per well Histone Extraction buffer (catalog # AL009F2;Perkin Elmer; Waltham, Mass.) was added and the plate further incubatedat RT for 20 min on plate shaker with low speed. To each well was thenadded 10 μL per well of a 5× mix of anti-K27me3 acceptor beads plusBiotinylated anti-Histone H3 (C-ter) Antibody (diluted to 3 nM final)(Catalog #AL118 Perkin Elmer; Waltham, Mass.). Dilution of the acceptorbeads and then anti-Histone H3 was with 1× Histone Detection buffer(Catalog # AL009F3 Perkin Elmer; Waltham, Mass.) which was produceddiluted from the 10× stock provided. The plate was sealed with analuminum plate sealer and incubated at 23° C. for 60 min. We then added10 μL 5× solution of Streptavidin Donor beads (Catalog #6760002 PerkinElmer; Waltham, Mass.) (20 μg/mL final in 1× Histone Detection Buffer),sealed the plate with Aluminum plate sealer and incubated at 23° C. for30 min. The plates were then read using an EnVision-Alpha Reader (model#2104 Perkin Elmer; Waltham, Mass.).

Cell viability was assayed by adding 15 μL of Cell Titer Glo ((Catalog#G7571 Promega Madison, Wis.) to each well with cells with media. Theplates were incubated foat RT for 15-20 minutes on a plate shaker at lowspeed. The plates were then read using an EnVision-Alpha Reader (model#2104 Perkin Elmer; Waltham, Mass.).

Data from both assays was analyzed using Assay Assistant (ConstellationPharmaceuticals In-house product) and Activity Base (IDBS Ltd, Surrey,UK) template. Data files were imported to Assay Assistant and assayconditions were specified. A unique Analysis ID was created and the datafiles exported to Activity Base. An analysis template was created onActivity Base to measure dose-dependent inhibition of H3K27me3 mark andcell viability respectively. Readout of DMSO wells were used tonormalize the data. Resulting curves were fitted using Activity basesoftware Model 205 (IDBS Ltd, Surrey, UK). The data was checked forquality, validated and integrated in excel format using SARview (IDBSLtd, Surrey, UK).

Table 3 shows the activity of selected compounds of this invention inthe two different HeLa cell assays described above. EC₅₀ values arereported as follows: “A” indicates an EC₅₀ value of less than 400 nM;“B” indicates an EC₅₀ value of 400 nM to 2 μM; “C” indicates an EC₅₀value of greater than 2 μM and less than 10 μM for each enzyme; “D”indicates an EC₅₀ value of greater than 10 μM for each enzyme; and “*(XμM)” indicates that no inhibition was observed at the highestconcentration (i.e., X μM) of compound tested.

TABLE 3 Ec50 Values for Selected Compounds of the Invention In HelaCells Expressing H3k27 Mutant EZH2. Com- pound H3K27me3_Alpha_HeLa No.(EC50) H3K27me3_MSD_HeLa_(EC50) 204 B 211 B 212 B 218 A 219 B 224 A A230 B 240 C 241 B 243 C 253 A 256 B 261 A A 273 A 284 B 288 A B 294 A A298 A A 300 A A 304 A A 310 A A 313 A A 314 A 315 D 316 B 317 A 321 A327 A 335 A 336 A 337 A 341 A 342 A 343 B 344 A 345 A 346 A 347 B 352 B355 A 356 A 357 A 358 B 359 B 360 C 362 A 363 A 364 *(3.33 μM) 365 A 366B 367 A 368 A 369 A 370 *(3.33 μM) 373 A 374 A 375 A 376 NaN 377 B

Example 18 Tumor Growth Inhibition Analysis

The anti-tumor efficacy of Compound 362 and 365 in the subcutaneousKarpas422 human lymphoma xenograft model in female CB-17 SCID mice wasas follows.

Animals

Species: Mus Musculus

Strain: CB-17 SCID miceAge: 6-8 weeksSex: femaleBody weight: 18-22 gNumber of animals: 50 mice plus spareAnimal supplier: Shanghai SLAC Laboratory Animal Co., LTD.

Cell Culture

The Karpas422 tumor cells were maintained in vitro as suspension culturein RPMI1640 medium supplemented with 10% heat inactivated fetal calfserum at 37° C. in an atmosphere of 5% CO₂ in air. The tumor cells wereroutinely subcultured twice weekly. The cells growing in an exponentialgrowth phase were harvested and counted for tumor inoculation.

Tumor Inoculation

Each mouse was inoculated subcutaneously at the right flank with theKarpas422 tumor cells (5×10⁶) in 0.2 ml of PBS with Matrigel (1:1) fortumor development. Day 23 after tumor inoculation was as day 0 after thestart of treatment when the average tumor size reached approximately 300mm³. Each group consisted of 10 tumor-bearing mice.

Tumor Measurements

Tumor size was measured three times weekly in two dimensions using acaliper, and the volume was expressed in mm³ using the formula: V=0.536a×b² where a and b are the long and short diameters of the tumor,respectively. The tumor size was then used for calculations of T/Cvalues. The T/C value (in percent) is an indication of antitumoreffectiveness; T and C are the mean volumes of the treated and controlgroups, respectively, on a given day. TGI was calculated for each groupusing the formula: TGI (%)=[1−(Ti−T0)/(Vi−V0)]×100; Ti is the averagetumor volume of a treatment group on a given day, T0 is the averagetumor volume of the treatment group on the day of treatment start, Vi isthe average tumor volume of the vehicle control group on the same daywith Ti, and V0 is the average tumor volume of the vehicle group on theday of treatment start.

Experimental Endpoint and Sample Collection

1). Plasma, tumor and muscle in EPZ-6438 group were collected on day 16after the start of treatment at 6 h after dosing. Plasma, tumor andmuscle in vehicle, CPI-524369, CPI-524416 and CPI-591780 groups werecollected on day 25 after the start of treatment at 1 h after dosing.2). All the blood was taken from each animal with EDTA-K2 asanticoagulant. Plasma was divided into two parts. The first part was forPK analysis; the second part was frozen for backup. 3). Tumor wasdivided into three parts. The first part was snap-frozen for PK; thesecond part was snap-frozen for PD analysis; the third part was frozenfor backup. 4). Muscle was divided into two parts. The first part wassnap-frozen for PK; the second part was frozen for backup.

Tumor Growth Inhibition Analysis

TABLE 4 Tumor growth inhibition calculation for Compounds 362 and 365 inthe karpass422 xenograft model calculated based on tumor volumemeasurements on day 25 or day 16 after the start of treatment Tumor Size(mm³)^(a) T/C^(b) TGI Treatment on day 25 (%) (%) Significance^(d)Vehicle 1704 ± 123 — — — Compound 362 385 ± 66 22.59 92.75 *** (160mg/kg) Compound 365 319 ± 67 18.72 97.25 *** (160 mg/kg) Note: ^(a)Mean± SEM. ^(b)Tumor Growth Inhibition is calculated by dividing the groupaverage tumor volume for the treated group by the group average tumorvolume for the control group (T/C). For a test article to be consideredto have anti-tumor activity, T/C must be 0.5 or less. ^(d)Statisticallysignificant difference (one-way ANOVA), vs vehicle: *** p < 0.001.

1. A compound having the structural Formula (II):

or a pharmaceutically acceptable salt thereof, wherein: A is CH or N;R^(1a) is selected from —C₁-C₂ alkyl and —O—(C₁-C₂ alkyl), whereinR^(1a) is optionally substituted with one or more fluoro; R^(4a) isselected from —(C₁-C₃ alkylene)-O—(C₁-C₂ alkyl),1-substituted-pipieridin-4-yl, C₃-C₆ cycloalkyl optionally substitutedwith one or more fluoro, and tetrahydropyranyl; and R¹³ is selected fromhydrogen, halo, phenyl, pyridinyl, and —O—(C₁-C₄ alkyl).
 2. The compoundof claim 1, wherein R^(1a) is selected from —OCH₃, —CH₃, —OCHF₂, and—CH₂CH₃.
 3. The compound of claim 1 or 2, wherein the1-substituted-pipieridin-4-yl is a 1-halo(C₁-C₃)alkyl-piperidin-4-yl. 4.The compound of any one of claims 1 to 3, wherein R^(4a) is selectedfrom —CH₂OCH₃, —CH(CH₃)OCH₃, 4,4-difluorocyclohexyl, cyclopropyl,tetrayhyrdopyran-4-yl, 1-(t-butoxycarbonyl)-piperidin-4-yl,1-(isobutoxycarbonyl)-piperidin-4-yl,1-(isopropoxycarbonyl)-piperidin-4-yl, 1-(2-fluoroethyl)-piperidin-4-yl,1-(2,2-difluoroethyl)-piperidin-4-yl,1-(2,2,2-trifluoroethyl)-piperidin-4-yl,1-(2-hydroxyisobutyl)-piperidin-4-yl,1-(hydroxyisopropylcarbonyl)-piperidin-4-yl,1-(ethoxycarbonylmethyl)-piperidin-4-yl,1-(isopropylcarbonyl)-piperidin-4-yl, 1-methylpiperidin-4-yl,1-(methylsulfonyl)-piperidin-4-yl, 1-(ethylsulfonyl)-piperidin-4-yl,1-(isopropylsulfonyl)-piperidin-4-yl, 1-(phenyl)-piperidin-4-yl,1-(oxetan-3-yl)piperidin-4-yl, 1-(pyridin-2-yl)-piperidin-4-yl, and1-(pyrimidin-2-yl)-piperidin-4-yl.
 5. The compound of any one of claims1 to 4, wherein R¹³ is selected from hydrogen, chloro, fluoro,—OCH(CH₃)₂, phenyl, and pyridin-2-yl.
 6. The compound of claim 1,wherein the compound isN-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide,or a pharmaceutically acceptable salt thereof.
 7. The compound of claim6, wherein the compound isR—N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide,or a pharmaceutically acceptable salt thereof.
 8. The compound of claim1, wherein the compound is1-(1-(1-(2,2-difluoroethyl)piperidin-4-yl)ethyl)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1H-indole-3-carboxamide,or a pharmaceutically acceptable salt thereof.
 9. The compound of claim8, wherein the compound isR-1-(1-(1-(2,2-difluoroethyl)piperidin-4-yl)ethyl)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1H-indole-3-carboxamide,or a pharmaceutically acceptable salt thereof.
 10. The compound of claim1, wherein the compound isN-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-(1-(1-(2-hydroxy-2-methylpropyl)piperidin-4-yl)ethyl)-2-methyl-1H-indole-3-carboxamide,or a pharmaceutically acceptable salt thereof.
 11. The compound of claim10, wherein the compound isR—N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-(1-(1-(2-hydroxy-2-methylpropyl)piperidin-4-yl)ethyl)-2-methyl-1H-indole-3-carboxamide,or a pharmaceutically acceptable salt thereof.
 12. The compound of claim1, wherein the compound is1-(1-(1-ethylpiperidin-4-yl)ethyl)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1H-indole-3-carboxamide,or a pharmaceutically acceptable salt thereof.
 13. The compound of claim12, wherein the compound isR-1-(1-(1-ethylpiperidin-4-yl)ethyl)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1H-indole-3-carboxamide,or a pharmaceutically acceptable salt thereof.
 14. A pharmaceuticalcomposition comprising a compound of any one of claims 1 to 13, or apharmaceutically acceptable salt thereof; and a pharmaceuticallyacceptable carrier.
 15. Use of a compound of any one of claims 1 to 13,or a pharmaceutically acceptable salt thereof, for the preparation of amedicament for treating a disease or disorder associated with cellularproliferation.
 16. The use of claim 15, wherein the disease is cancer.17. The use of claim 16, wherein the cancer is selected from breastcancer, prostate cancer, colon cancer, renal cell carcinoma,glioblastoma multiforme cancer, bladder cancer, melanoma, bronchialcancer, lymphoma, and liver cancer.